

---

---

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549**

---

**FORM 10-Q**

(Mark One)

QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2021

OR

TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from \_\_\_\_\_ to \_\_\_\_\_

Commission File Number: **001-38546**

---

**NEURONETICS, INC.**

(Exact name of registrant as specified in its charter)

---

**Delaware**  
(State or other jurisdiction of  
incorporation or organization)

**33-1051425**  
(I.R.S. Employer Identification No.)

**3222 Phoenixville Pike, Malvern, PA**  
(Address of principal executive offices)

**19355**  
(Zip Code)

**(610) 640-4202**  
(Registrant's telephone number, including area code)

**Not applicable.**

(Former name, former address and former fiscal year, if changed since last report)

Securities registered pursuant to Section 12(b) of the Act:

Title of each class	Trading Symbol (s)	Name on each exchange on which registered
Common Stock (\$0.01 par value)	STIM	The Nasdaq Global Market

---

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes  No

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes  No

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of "large accelerated filer," "accelerated filer," "smaller reporting company," and "emerging growth company" in Rule 12b-2 of the Exchange Act.

Large accelerated filer  Accelerated filer   
Non-accelerated filer  Smaller reporting company   
Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes  No

There were 25,759,895 shares of the registrant's common stock outstanding as of April 29, 2021.

---

---

NEURONETICS, INC.

Quarterly Report on Form 10-Q for the quarterly period ended March 31, 2021

Table of Contents

	<u>Page</u>	
<u>PART I – FINANCIAL INFORMATION</u>		
<u>Item 1.</u>	<u>Financial Statements.</u>	3
	<u>Balance Sheets as of March 31, 2021 and December 31, 2020</u>	3
	<u>Statements of Operations for the Three Months ended March 31, 2021 and 2020</u>	4
	<u>Statements of Changes in Stockholders' Equity for the Three Months ended March 31, 2021 and 2020</u>	5
	<u>Statements of Cash Flows for the Three Months ended March 31, 2021 and 2020</u>	6
	<u>Notes to Interim Financial Statements</u>	7
	<u>Management's Discussion and Analysis of Financial Condition and Results of Operations.</u>	20
<u>Item 2.</u>	<u>Quantitative and Qualitative Disclosures About Market Risk.</u>	32
<u>Item 3.</u>	<u>Controls and Procedures.</u>	32
	<u>PART II – OTHER INFORMATION</u>	
<u>Item 1.</u>	<u>Legal Proceedings.</u>	33
<u>Item 1A</u>	<u>Risk Factors</u>	33
<u>Item 2.</u>	<u>Unregistered Sales of Equity Securities and Use of Proceeds.</u>	33
<u>Item 3.</u>	<u>Defaults Upon Senior Securities.</u>	33
<u>Item 4.</u>	<u>Mine Safety Disclosures.</u>	33
<u>Item 5.</u>	<u>Other Information.</u>	33
<u>Item 6.</u>	<u>Exhibits.</u>	34
	<u>SIGNATURES</u>	35

**PART I - FINANCIAL INFORMATION**

**Item 1. Financial Statements.**

**NEURONETICS, INC.**  
**Balance Sheets**  
(Unaudited; In thousands, except per share data)

	March 31, 2021	December 31, 2020
<b>Assets</b>		
Current assets:		
Cash and cash equivalents	\$ 121,277	\$ 48,957
Accounts receivable, net	6,964	7,166
Inventory	5,401	3,720
Current portion of net investments in sales-type leases	1,930	1,887
Current portion of prepaid commission expense	1,135	1,096
Prepaid expenses and other current assets	2,239	2,186
Total current assets	<u>138,946</u>	<u>65,012</u>
Property and equipment, net	866	730
Operating lease right-of-use assets	3,320	3,418
Net investments in sales-type leases	1,958	2,331
Prepaid commission expense	5,255	5,300
Other assets	1,962	1,866
Total Assets	<u>\$ 152,307</u>	<u>\$ 78,657</u>
<b>Liabilities and Stockholders' Equity</b>		
Current liabilities:		
Accounts payable	\$ 3,241	\$ 3,749
Accrued expenses	5,152	7,319
Deferred revenue	1,912	2,020
Current portion of operating lease liabilities	602	594
Current portion of long-term debt, net	—	—
Total current liabilities	<u>10,907</u>	<u>13,682</u>
Long-term debt, net	34,791	34,620
Deferred revenue	1,614	1,741
Operating lease liabilities	3,024	3,121
Total Liabilities	<u>50,336</u>	<u>53,164</u>
Commitments and contingencies (Note 16)	—	—
Stockholders' Equity:		
Preferred stock, \$0.01 par value: 10,000 shares authorized; no shares issued or outstanding at March 31, 2021 and December 31, 2020	—	—
Common stock, \$0.01 par value: 200,000 shares authorized; 25,756 and 19,114 shares issued and outstanding at March 31, 2021 and December 31, 2020, respectively	258	191
Additional paid-in capital	387,134	302,842
Accumulated deficit	<u>(285,421)</u>	<u>(277,540)</u>
Total Stockholders' Equity	<u>101,971</u>	<u>25,493</u>
Total Liabilities and Stockholders' Equity	<u>\$ 152,307</u>	<u>\$ 78,657</u>

The accompanying notes are an integral part of these unaudited interim financial statements.

**NEURONETICS, INC.**  
**Statements of Operations**  
**(Unaudited; In thousands, except per share data)**

	Three Months Ended	
	March 31,	
	2021	2020
Revenues	\$ 12,288	\$ 11,476
Cost of revenues	2,221	2,811
Gross Profit	<u>10,067</u>	<u>8,665</u>
Operating expenses:		
Sales and marketing	8,561	10,723
General and administrative	6,104	5,287
Research and development	<u>2,311</u>	<u>3,021</u>
Total operating expenses	16,976	19,031
Loss from Operations	<u>(6,909)</u>	<u>(10,366)</u>
Other (income) expense:		
Interest expense	985	1,523
Loss on extinguishment of debt	—	924
Other income, net	<u>(13)</u>	<u>(200)</u>
Net Loss	\$ (7,881)	\$ (12,613)
Net loss per share of common stock outstanding, basic and diluted	<u>\$ (0.31)</u>	<u>\$ (0.68)</u>
Weighted-average common shares outstanding, basic and diluted	<u>25,150</u>	<u>18,681</u>

The accompanying notes are an integral part of these unaudited interim financial statements.

**NEURONETICS, INC.**  
**Statements of Changes in Stockholders' Equity**  
**(Unaudited; In thousands)**

	Common Stock		Additional Paid-in Capital	Accumulated Deficit	Total Stockholders' Equity
	Shares	Amount			
Balance at December 31, 2019	18,645	\$ 186	\$ 297,753	\$ (250,087)	\$ 47,852
Share-based awards and options exercises	81	1	75	—	76
Share-based compensation expense	—	—	1,196	—	1,196
Net loss	—	—	—	(12,613)	(12,613)
Balance at March 31, 2020	<u>18,726</u>	<u>\$ 187</u>	<u>\$ 299,024</u>	<u>\$ (262,700)</u>	<u>\$ 36,511</u>
Balance at December 31, 2020	19,114	\$ 191	\$ 302,842	\$ (277,540)	\$ 25,493
Share-based awards and options exercises	1,076	11	1,581	—	1,592
Issuance of common stock, net of issuance costs of \$401	5,566	56	80,515	—	80,571
Share-based compensation expense	—	—	2,196	—	2,196
Net loss	—	—	—	(7,881)	(7,881)
Balance at March 31, 2021	<u>25,756</u>	<u>\$ 258</u>	<u>\$ 387,134</u>	<u>\$ (285,421)</u>	<u>\$ 101,971</u>

The accompanying notes are an integral part of these unaudited interim financial statements.

**NEURONETICS, INC.**  
**Statements of Cash Flows**  
**(Unaudited; In thousands)**

	<b>Three Months Ended March 31,</b>	
	<b>2021</b>	<b>2020</b>
<b>Cash Flows from Operating Activities:</b>		
Net loss	\$ (7,881)	\$ (12,613)
<b>Adjustments to reconcile net loss to net cash used in operating activities:</b>		
Depreciation and amortization	281	301
Share-based compensation	2,196	1,196
Non-cash interest expense	171	782
Cost of rental units purchased by customers	99	70
Loss on extinguishment of debt	—	622
<b>Changes in certain assets and liabilities:</b>		
Accounts receivable, net	202	383
Inventory	(1,681)	(104)
Net investments in sales-type leases	330	(368)
Leasehold reimbursement	—	836
Prepaid commission expense	6	(419)
Prepaid expenses and other assets	206	285
Accounts payable	(694)	(1,299)
Accrued expenses	(2,168)	(3,227)
Deferred revenue	(235)	(95)
<b>Net Cash Used in Operating Activities</b>	<b>(9,168)</b>	<b>(13,650)</b>
<b>Cash Flows from Investing Activities:</b>		
Purchases of property and equipment and capitalized software	(675)	(266)
<b>Net Cash Used in Investing Activities</b>	<b>(675)</b>	<b>(266)</b>
<b>Cash Flows from Financing Activities:</b>		
Proceeds from issuance of long-term debt	—	35,000
Repayment of long-term debt	—	(32,500)
Payments of debt issuance costs	—	(721)
Proceeds from exercises of stock options	1,592	76
Proceeds from the issuance of common stock	80,972	—
Payments of common stock offering issuance costs	(401)	—
<b>Net Cash Provided by Financing Activities</b>	<b>82,163</b>	<b>1,855</b>
<b>Net Increase (Decrease) in Cash and Cash Equivalents</b>	<b>72,320</b>	<b>(12,061)</b>
Cash and Cash Equivalents, Beginning of Period	48,957	75,708
<b>Cash and Cash Equivalents, End of Period</b>	<b>\$ 121,277</b>	<b>\$ 63,647</b>
<b>Supplemental disclosure of cash flow information:</b>		
Cash paid for interest	\$ 814	\$ 1,403
<b>Supplemental disclosure of non-cash investing and financing activities:</b>		
Purchases of property and equipment and capitalized software in accounts payable and accrued expenses	\$ 186	\$ 94

The accompanying notes are an integral part of these unaudited interim financial statements.

**NEURONETICS, INC.**  
**Notes to Interim Financial Statements**  
**(Unaudited)**

**1. DESCRIPTION OF BUSINESS**

Neuronetics, Inc., or the Company, is a commercial stage medical technology company focused on designing, developing and marketing products that improve the quality of life for patients who suffer from psychiatric disorders. The Company's first commercial product, the NeuroStar Advanced Therapy System, is a non-invasive and non-systemic office-based treatment that uses transcranial magnetic stimulation, or TMS, to create a pulsed, MRI-strength magnetic field that induces electrical currents designed to stimulate specific areas of the brain associated with mood. The system was cleared in 2008 by the United States Food and Drug Administration, or the FDA, to treat adult patients with major depressive disorder, or MDD, who have failed to achieve satisfactory improvement from prior antidepressant medication in the current episode. NeuroStar Advanced Therapy is also available in other parts of the world, including Japan, where it is listed under Japan's national health insurance. The Company intends to continue to pursue development of its NeuroStar Advanced Therapy System for additional indications.

**COVID-19**

The Company is continuing to monitor the impact of the COVID-19 pandemic on all aspects of its business and geographies, including how it will continue to impact the Company's customers, supply chain, employees and other business partners. While the Company began to experience significant disruptions in March 2020 through the end of March 2021 from the COVID-19 pandemic, it is unable to predict the full impact that the pandemic may have on its financial condition, results of operations and cash flows due to numerous uncertainties. These uncertainties include the scope, severity and duration of the pandemic, the actions taken to contain the pandemic or mitigate its impact and the direct and indirect economic effects of the pandemic and containment measures, among others. The pandemic has significantly adversely impacted global economic activity and has contributed to significant volatility and negative pressure in financial markets, and may contribute to periods of economic uncertainty in the future.

The Company applied for and received a \$6.4 million loan in April 2020 under the Paycheck Protection Program (the "PPP") established by the Coronavirus Aid, Relief, and Economic Security Act ("CARES Act") on March 27, 2020. Due to questions concerning the eligibility of public companies similarly situated to the Company, on May 7, 2020, the Company repaid the loan in full, including interest accrued to date.

**Liquidity**

As of March 31, 2021, the Company had cash and cash equivalents of \$121.3 million and an accumulated deficit of \$285.4 million. The Company incurred negative cash flows from operating activities of \$28.4 million for the year ended December 31, 2020 and \$9.2 million for the three months ended March 31, 2021. The Company has incurred operating losses since its inception, and management anticipates that its operating losses will continue in the near term as the Company continues to invest in sales, marketing and product development activities. The Company's primary sources of capital to date have been proceeds from its IPO, private placements of its convertible preferred securities, borrowings under its credit facilities, proceeds from its secondary public offering of common stock, revenues from sales of its products and other public offerings of the Company's common stock. As of March 31, 2021, the Company had \$35.0 million of borrowings outstanding under its credit facility, which has a final maturity in February 2025. Management believes that the Company's cash and cash equivalents as of March 31, 2021, and anticipated revenues from sales of its products are sufficient to fund the Company's operations for at least the next 12 months from the issuance of these financial statements.

**2. BASIS OF PRESENTATION**

The accompanying financial statements have been prepared in accordance with United States generally accepted accounting principles, or GAAP. Any reference in these notes to applicable guidance is meant to

**NEURONETICS, INC.**  
**Notes to Interim Financial Statements**  
**(Unaudited)**

refer to GAAP as found in the Accounting Standards Codification, or ASC, and Accounting Standards Updates, or ASUs, promulgated by the Financial Accounting Standards Board, or FASB.

**Interim Financial Statements**

The accompanying unaudited interim financial statements have been prepared from the books and records of the Company in accordance with GAAP for interim financial information and Rule 10-01 of Regulation S-X promulgated by the United States Securities and Exchange Commission, or SEC, which permit reduced disclosures for interim periods. All adjustments, consisting only of normal recurring adjustments, necessary for a fair presentation of the accompanying balance sheets and statements of operations and stockholders' deficit and cash flows have been made. Although these interim financial statements do not include all of the information and footnotes required for complete annual financial statements, management believes the disclosures are adequate to make the information presented not misleading. Unaudited interim results of operations and cash flows for the three months ended March 31, 2021 are not necessarily indicative of the results that may be expected for the full year. Unaudited interim financial statements and footnotes should be read in conjunction with the audited financial statements and footnotes included in the Company's Form 10-K filed with the SEC on March 2, 2021, wherein a more complete discussion of significant accounting policies and certain other information can be found.

**Use of Estimates**

The preparation of financial statements in accordance with GAAP and the rules and regulations of the SEC requires the use of estimates and assumptions, based on judgments considered reasonable, which affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. The Company bases its estimates and assumptions on historical experience, known trends and events and various other factors that management believes to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying value of assets and liabilities that are not readily apparent from other sources. Although management believes its estimates and assumptions are reasonable when made, they are based upon information available at the time they are made. Management evaluates the estimates and assumptions on an ongoing basis and, if necessary, makes adjustments. Due to the risks and uncertainties involved in the Company's business and evolving market conditions, including those related to the COVID-19 pandemic, and given the subjective element of the estimates and assumptions made, actual results may differ materially from estimated results.

**3. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES**

The Company's complete summary of significant accounting policies can be found in "Note 3. Summary of Significant Accounting Policies" in the audited financial statements included in the Company's Form 10-K filed with the SEC on March 2, 2021.

**4. RECENT ACCOUNTING PRONOUNCEMENTS**

***New Accounting Standards Not Yet Adopted by the Company***

In June 2016, the FASB issued ASU 2016-13, *Financial Instruments - Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments* ("Topic 326"). This ASU provides guidance for recognizing credit losses on financial instruments based on an estimate of current expected credit losses model. The FASB subsequently issued ASU 2019-04, to clarify and address certain items related to the amendments in Topic 326.

ASU 2019-05, *Financial Instruments - Credit Losses (Topic 326): Targeted Transition Relief*, was issued to provide entities that have certain instruments within the scope of ASC 326 with an option to irrevocably elect

**NEURONETICS, INC.**  
**Notes to Interim Financial Statements**  
**(Unaudited)**

the fair value option under *ASC 825-10, Financial Instruments - Overall*, applied on an instrument-by-instrument basis for eligible instruments. ASU 2019-10, Topic 326, Topic 815, and Topic 842 amends the mandatory effective date for Topic 326.

These ASUs are effective for fiscal years beginning after December 15, 2022 for entities that are eligible to be defined by the SEC as a smaller reporting company. The Company is a smaller reporting company. Although the impact upon adoption will depend on the financial instruments held by the Company at that time, the Company does not anticipate a significant impact on its financial statements based on the instruments currently held and its historical trend of bad debt expense relating to trade accounts receivable.

Other than the items noted above, there have been no new accounting pronouncements not yet effective or adopted in the current year that we believe have a significant impact, or potential significant impact, to our unaudited interim financial statements

**5. FAIR VALUE MEASUREMENT AND FINANCIAL INSTRUMENTS**

The carrying values of cash equivalents, accounts receivable, prepaids and other current assets, and accounts payable on the Company's balance sheets approximated their fair values as of March 31, 2021 and December 31, 2020 due to their short-term nature. The carrying values of the Company's credit facility approximated its fair value as of March 31, 2021 and December 31, 2020 due to its variable interest rate.

Certain of the Company's financial instruments are measured at fair value using a three-level hierarchy that prioritizes the inputs used to measure fair value. This hierarchy maximizes the use of observable inputs and minimizes the use of unobservable inputs. The three levels of inputs used to measure fair value are as follows:

Level 1: Inputs are quoted prices for identical instruments in active markets.

Level 2: Inputs are quoted prices for similar instruments in active markets; quoted prices for identical or similar instruments in markets that are not active; or model-derived valuations whose inputs are observable or whose significant value drivers are observable.

Level 3: Inputs are unobservable and reflect the Company's own assumptions, based on the best information available, including the Company's own data.

**NEURONETICS, INC.**  
**Notes to Interim Financial Statements**  
(Unaudited)

The following tables set forth the carrying amounts and fair values of the Company's financial instruments as of March 31, 2021 and December 31, 2020 (in thousands):

	March 31, 2021				
	Carrying Amount	Fair Value	Fair Value Measurement Based on		
			Quoted Prices In Active Markets (Level 1)	Significant other Observable Inputs (Level 2)	Significant Unobservable Inputs (Level 3)
<b>Assets</b>					
Money market funds (cash equivalents)	\$ 118,121	\$ 118,121	\$ 118,121	\$ —	\$ —

  

	December 31, 2020				
	Carrying Amount	Fair Value	Fair Value Measurement Based on		
			Quoted Prices In Active Markets (Level 1)	Significant other Observable Inputs (Level 2)	Significant Unobservable Inputs (Level 3)
<b>Assets</b>					
Money market funds (cash equivalents)	\$ 47,117	\$ 47,117	\$ 47,117	\$ —	\$ —

**6. ACCOUNTS RECEIVABLE**

The following table presents the composition of accounts receivable, net as of March 31, 2021 and December 31, 2020 (in thousands):

	March 31, 2021	December 31, 2020
Gross accounts receivable - trade	\$ 7,713	\$ 8,178
Less: Allowances for doubtful accounts	(749)	(1,012)
Accounts receivable, net	<u>\$ 6,964</u>	<u>\$ 7,166</u>

**7. PROPERTY AND EQUIPMENT AND CAPITALIZED SOFTWARE**

The following table presents the composition of property and equipment, net as of March 31, 2021 and December 31, 2020 (in thousands):

	March 31, 2021	December 31, 2020
Laboratory equipment	\$ 150	\$ 150
Office equipment	497	487
Computer equipment and software	1,495	1,360
Manufacturing equipment	445	273
Leasehold improvements	459	459
Rental equipment	207	405
Property and equipment, gross	3,253	3,134
Less: Accumulated depreciation	(2,387)	(2,404)
Property and equipment, net	<u>\$ 866</u>	<u>\$ 730</u>

As of March 31, 2021 and December 31, 2020, the Company had capitalized software costs, net of \$1.4 million and \$1.2 million, respectively, which are included in "Other assets" on the balance sheet.

**NEURONETICS, INC.**  
**Notes to Interim Financial Statements**  
**(Unaudited)**

Depreciation and amortization expense was \$0.3 million for the three months ended March 31, 2021 and 2020, respectively.

## 8. LEASES

### *Lessee:*

The Company has operating leases for its corporate headquarters and office equipment, including copiers. The Company leases approximately 32,000 square foot facility in Malvern, Pennsylvania for its corporate headquarters, which includes office and warehouse space. The Company does not currently have any finance leases or executed leases that have not yet commenced.

Operating lease rent expense was \$0.2 million and \$0.2 million for the three months ended March 31, 2021 and 2020, respectively. As of March 31, 2021, the weighted-average remaining lease term of operating leases was 6.9 years and the weighted-average discount rate was 6.5%.

In the first quarter of 2020, the Company received a reimbursement of \$0.8 million for leasehold expenses previously incurred in connection with the lease agreement for its Malvern facility. The reimbursement was recorded as an offset to the non-current lease liability that was established when the lease agreement was executed.

The following table presents the supplemental cash flow information as a lessee related to leases (in thousands):

	<b>Three Months Ended</b>	
	<b>March 31, 2021</b>	<b>March 31, 2020</b>
Cash paid for amounts included in the measurement of lease liabilities:		
Operating cash flows from operating leases	\$ 132	\$ 126

The following table sets forth by year the required future payments of operating lease liabilities (in thousands):

	<b>March 31, 2021</b>
Remainder of 2021	\$ 472
2022	642
2023	637
2024	646
2025	660
Thereafter	1,487
Total lease payments	4,544
Less imputed interest	(918)
Present value of operating lease liabilities	<u>\$ 3,626</u>

### *Lessor sales-type leases:*

Certain customers have purchased NeuroStar Advanced Therapy Systems on a rent-to-own basis. The lease term is three years with a customer option to purchase the NeuroStar Advanced Therapy System at the end of the lease or automatic transfer of ownership of the NeuroStar Advanced Therapy System at the end of the lease.

**NEURONETICS, INC.**  
**Notes to Interim Financial Statements**  
**(Unaudited)**

The following table sets forth the profit recognized on sales-type leases (in thousands):

	Three Months Ended March 31,	
	2021	2020
Profit recognized at commencement, net	\$ 133	\$ 252
Interest income	—	—
<b>Total sales-type lease income</b>	<b>\$ 133</b>	<b>\$ 252</b>

The following table sets forth a maturity analysis of the undiscounted lease receivables related to sales-type leases (in thousands):

	March 31, 2021
Remainder of 2021	\$ 1,576
2022	1,673
2023	599
2024	40
<b>Total sales-type lease receivables</b>	<b>\$ 3,888</b>

As of March 31, 2021, the carrying amount of the lease receivables is \$3.9 million. The Company does not have any unguaranteed residual assets.

*Lessor operating leases:*

NeuroStar Advanced Therapy Systems sold on a rent-to-own basis prior to January 1, 2019 are accounted for as operating leases. For the three months ended March 31, 2021 and 2020, the Company recognized operating lease income of \$0.1 million and \$0.1 million, respectively.

The following table sets forth a maturity analysis of its undiscounted lease receivables related to operating leases as of March 31, 2021 (in thousands):

	March 31, 2021
Remainder of 2021	\$ 39
<b>Total lease receivables</b>	<b>\$ 39</b>

The Company maintained Rental Equipment, net of \$0.1 million and \$0.2 million, as of March 31, 2021 and December 31, 2020, respectively, which are included in "Property and equipment, net" on the balance sheet. Rental equipment depreciation expense was \$0.01 million and \$0.03 million for the three months ended March 31, 2021 and 2020, respectively.

## **9. PREPAID COMMISSION EXPENSE**

The Company pays a commission on both NeuroStar Advanced System sales and Treatment Session sales. Since the commission paid for System sales is not commensurate with the commission paid for Treatment Sessions, the Company capitalizes commission expense associated with NeuroStar Advanced Therapy System sales commissions paid that is incremental to specifically anticipated future Treatment Session orders. In developing this estimate, the Company considered its historical Treatment Session sales and customer retention rates, as well as technology development life cycles and other industry factors. These costs are periodically reviewed for impairment.

**NEURONETICS, INC.**  
**Notes to Interim Financial Statements**  
**(Unaudited)**

NeuroStar Advanced Therapy System commissions are deferred and amortized on a straight-line basis over a seven year period equal to the average customer term, which the Company deems to be the expected period of benefit for these costs.

On the Company's balance sheets, the current portion of capitalized contract costs is represented by the current portion of prepaid commission expense, while the long-term portion is included in prepaid commission expense. Amortization expense was \$0.3 million and \$0.2 million for the three months ended March 31, 2021 and 2020, respectively.

#### 10. ACCRUED EXPENSES

The following table presents the composition of accrued expenses as of March 31, 2021 and December 31, 2020 (in thousands):

	March 31, 2021	December 31, 2020
Compensation and related benefits	\$ 3,040	\$ 5,023
Consulting and professional fees	396	292
Research and development expenses	249	138
Warranty	457	536
Sales and other taxes payable	640	726
Other	370	604
Accrued expenses	<u>\$ 5,152</u>	<u>\$ 7,319</u>

#### 11. DEFERRED REVENUE

Payment terms typically require payment upon shipment or installation of the System and additional payments as access codes for Treatment Sessions are delivered, which can span several years after the System is first delivered and installed. The timing of revenue recognition compared to billings and cash collections typically results in accounts receivable. However, sometimes customer advances and deposits might be required for certain customers and are recorded as deferred revenue. For multi-year agreements, the Company generally invoices customers annually at the beginning of each annual coverage period and recognizes revenue over the term of the coverage period.

As of March 31, 2021, the Company expects to recognize approximately the following percentages of deferred revenue by year:

Year:	Revenue Recognition
Remainder of 2021	44 %
2022	18 %
2023	17 %
2024	17 %
2025	4 %
Thereafter	- %
Total	<u>100 %</u>

Revenue recognized for the three months ended March 31, 2021 that was included in the contract liability balance at the beginning of the year was \$1.2 million, and primarily represented revenue earned from separately priced extended warranties, rent-to-own revenue, milestone revenue, and clinical training.

**NEURONETICS, INC.**  
**Notes to Interim Financial Statements**  
**(Unaudited)**

### Customers

For the three months ended March 31, 2021, one customer accounted for more than 10% of the Company's revenues.

## 12. DEBT

The following table presents the composition of debt as of March 31, 2021 and December 31, 2020 (in thousands):

	March 31, 2021	December 31, 2020
Outstanding principal	\$ 35,000	\$ 35,000
Accrued final payment fees	1,925	1,925
Less debt discounts	<u>(2,134)</u>	<u>(2,305)</u>
Total debt, net	34,791	34,620
Less current portion	—	—
Long-term debt, net	<u>\$ 34,791</u>	<u>\$ 34,620</u>

For the three months ended March 31, 2021, the Company recognized interest expense of \$1.0 million, of which \$0.8 million was cash and \$0.2 million was non-cash interest expense related to the amortization of deferred debt issuance costs and accrual of final payment fees.

For the three months ended March 31, 2020, the Company recognized interest expense of \$1.5 million, of which \$1.4 million was cash paid for interest during the period and \$0.1 million was non-cash interest expense related to the amortization of deferred debt issuance costs and accrual of final payment fees.

### Solar Credit Facility

On March 2, 2020, the "Company entered into a loan and security agreement with Solar Capital Ltd., or Solar, as collateral agent, and other lenders defined in the agreement, for a credit facility, or the Solar Facility, that replaced the Company's previous \$35.0 million credit facility with Oxford Finance LLC, or Oxford, and such facility, the Oxford Facility.

The Solar Facility permits the Company to borrow up to an aggregate amount of \$50.0 million in two tranches of term loans, a "Term A Loan" and "Term B Loan." On March 2, 2020, the Company borrowed an aggregate amount of \$35.0 million, which was the aggregate amount available under the Term A Loan portion of the Solar Facility. The Term A Loan portion of the Solar Facility matures, and all amounts borrowed thereunder are due, on February 28, 2025. Under the Term B Loan portion of the Solar Facility, the Company is permitted to borrow, at its election, up to an aggregate amount of \$15.0 million, (i) upon the Company achieving a specified amount of trailing twelve months net product revenue, and (ii) assuming there has been no event of default under the Solar Facility prior to such election. Once the net product revenue condition has been satisfied, the Company may only make an election to borrow under the Term B Loan portion of the Solar Facility until the earlier of (a) December 15, 2021, (b) 30 days following achievement of the net product revenue condition or (c) the occurrence of an event of default.

**NEURONETICS, INC.**  
**Notes to Interim Financial Statements**  
**(Unaudited)**

Each of the Term A Loan and Term B Loan accrue interest from the date of borrowing through the date of repayment at a floating per annum rate of interest, which resets monthly and is equal to 7.65% plus the greater of (a) 1.66% or (b) the rate per annum rate published by the Intercontinental Exchange Benchmark Administration Ltd. The Term A Loan and the Term B Loan both include an interest-only period through March 1, 2022, after which time the Company will be required to make monthly payments of principal and interest. Monthly principal payments are to be paid in equal amounts on a pro rata basis to lenders. At the Company's election, the interest only period may be extended through February 2023 if the Company satisfies a minimum net product revenue covenant through March 1, 2022 and no event of default shall have occurred.

In addition to the principal and interest payments due under the Solar Facility, the Company is required to pay a final payment fee to Solar due upon the earlier of prepayment, acceleration or the maturity date of the Term A Loan or Term B Loan portion of the Solar Facility equal to 5.50% of the principal amount of the term loans actually funded. The Company is accruing the final payment fees using the effective interest rate, with a charge to non-cash interest expense, over the term of borrowing. If the Company prepays either the of the Term A Loan or Term B Loan prior to their respective scheduled maturities, the Company will also be required to pay prepayment fees to Solar equal to 3% of the principal amount of such term loan then-prepaid if prepaid on or before the first anniversary of funding, 2% of the principal amount of such term loan then-prepaid if prepaid after the first anniversary and on or before the second anniversary of funding, or 1% of the principal amount of such term loan then-prepaid if prepaid after the second anniversary of funding of the principal amounts borrowed.

The Company is also required to pay Solar an exit fee upon the occurrence, prior to March 2, 2030, of (a) any liquidation, dissolution or winding up of the Company, (b) transaction that results in a person obtaining control over the Company, (c) the Company achieving \$100 million in trailing twelve month net product revenue or (d) the Company achieving \$125 million in trailing twelve month net product revenue. The exit fee for liquidation, dissolution, winding up or change of control of the Company is equal to 4.50% of the principal amount of the term loans actually funded. The exit fee for achieving either \$100 million or \$125 million in trailing twelve-month net product revenue is equal to 2.25% of the principal amount of the term loans actually funded or, if both net product revenue milestones are achieved, 4.50% of the principal amount of the term loans actually funded. The exit fee is capped at 4.50% of the principal amount of the term loans actually funded.

On December 8, 2020, the Company, Solar Capital Ltd., and our other lenders defined in the Solar Facility, executed an amendment to the Solar Facility (the "Solar Amendment"). The Solar Amendment divides the aggregate Term B Loan borrowing amount of \$15.0 million allowable upon our achievement of specific trailing twelve-month net product revenue targets into three separate \$5.0 million tranches ("Amended Term B Loan", "Term C Loan" and "Term D Loan"). The three tranches are available through June 20, 2021, December 20, 2021, and June 20, 2022, respectively, based on the achievement of agreed upon trailing twelve-month net product revenue targets for each tranche.

The Solar Amendment also reduces the trailing twelve-month net product revenue requirement for the Amended Term B Loan portion of the facility. Subject to certain conditions, the Company has the ability to extend the interest-only period on the initial Term A Loan to 36 months from 24 months upon achieving the revenue targets associated with the Amended Term B Loan. As of March 31, 2021, the Company is in compliance with the required minimum net product revenue covenant and anticipates electing to extend the interest-only period through March 1, 2023 for the Term A Loan, subject to continuing to meet the required conditions through and as of March 1, 2022. The Company is projected to be in compliance with the required covenant. The Company was required to pay an amendment fee of \$0.1 million to Solar, which has been recognized as a deferred debt issuance cost as of December 31, 2020 that will be amortized to interest expense using the effective interest method.

**NEURONETICS, INC.**  
**Notes to Interim Financial Statements**  
**(Unaudited)**

The Company's obligations under the Solar Facility are secured by a first priority security interest in substantially all of its assets, including its intellectual property. The loan and security agreement requires the Company to comply with certain financial covenants as well as customary affirmative and negative covenants.

The Solar Facility contains events of default, including, without limitation, events of default upon: (i) failure to make payment pursuant to the terms of the agreement; (ii) violation of covenants; (iii) material adverse changes to the Company's business; (iv) attachment or levy on the Company's assets or judicial restraint on its business; (v) insolvency; (vi) material cross-defaults; (vii) significant judgments, orders or decrees for payments by the Company not covered by insurance; (viii) incorrectness of representations and warranties; (ix) incurrence of subordinated debt; (x) a termination or breach of a guaranty; (xi) revocation of governmental approvals necessary for the Company to conduct its business; and (xii) failure by the Company to maintain a valid and perfected lien on the collateral securing the borrowing. The Solar Facility includes subjective acceleration clauses which permit the lenders to accelerate the maturity date under certain circumstances, including, but not limited to, material adverse effects on a Company's financial status or otherwise.

The Solar Facility includes a financial covenant requiring the attainment of a minimum trailing net revenue amount beginning on December 31, 2020. The Company and lenders executed the Solar Amendment in December 2020 that reduced the minimum trailing net revenue covenant requirement amounts beginning on December 31, 2020 to allow the Company to maintain compliance with the covenant as of December 31, 2020. As of March 31, 2021, the Company is in compliance with the financial covenant and is projected to be in compliance with the reduced minimum revenue covenant amounts going forward.

As of March 31, 2021, the Company is in compliance with all covenants in the Solar Facility.

**Oxford Credit Facility**

Prior to March 2020, the Company had a \$35.0 million credit facility in place with Oxford, which it entered into in March 2017 and that allowed it to borrow up to \$35.0 million in three tranches of term loans: a Term A Loan in the amount of \$25 million, which was drawn immediately upon closing in March 2017, a Term B Loan in the amount of \$5.0 million, which was drawn down in December 2017, and a Term C Loan in the amount of \$5.0 million which was never drawn down. Each term loan accrued interest from the date of borrowing through the date of repayment at a floating per annum rate of interest, which reset monthly and was equal to the greater of (a) 8.15% or (b) the 30 day U.S. LIBOR on the last business day of the month plus 7.38%. This facility featured an interest-only period on all tranches through March 2019.

In addition to principal and interest payments due under the \$35.0 million Oxford credit facility, the Company was required to make final payment fees to Oxford upon the earlier of prepayment or maturity and equal to 8.5% and 7.5% of the principal amounts of the Term A and Term B Loans, respectively. The Company accrued final payment fees using the effective interest rate, with a charge to non-cash interest expense, over the term of borrowing and until its entry into the Solar credit facility in March 2020, at which time the Company paid Oxford \$2.5 million in satisfaction of all final payment fee liabilities due under the Oxford credit facility.

The Company evaluated whether the Solar Facility entered into in March 2020 represented a debt modification or extinguishment in accordance with ASC 470-50, Debt—Modifications and Extinguishments and determined that the existing debt was extinguished as a result of the full repayment of the existing facility and concurrent issuance of a new credit facility with a new lender. The unamortized balance of the Company's combined debt discount and deferred issuance costs of \$0.6 million related to the Oxford facility were accounted for as a loss on extinguishment of debt in March 2020.

**NEURONETICS, INC.**  
**Notes to Interim Financial Statements**  
**(Unaudited)**

### 13. COMMON STOCK

#### Common Stock Offering

On February 2, 2021, we closed on our public offering and sale (the "Offering") of our common stock in which we issued and sold 5,566,000 shares of our common stock, which included shares pursuant to an option granted to underwriters to purchase additional shares, at a public offering price of \$15.50 per share. We received net proceeds of \$80.6 million after deducting underwriting discounts, commissions and offering expenses.

#### Common Stock

The following table summarizes the total number of shares of the Company's common stock issued and reserved for issuance as of March 31, 2021 and December 31, 2020 (in thousands):

	<u>March 31, 2021</u>	<u>December 31, 2020</u>
Shares of common stock issued	25,756	19,114
Shares of common stock reserved for issuance for:		
Common stock warrants outstanding	75	105
Stock options outstanding	1,806	2,365
Restricted stock units and awards outstanding	2,337	1,860
Shares available for grant under stock incentive plan	2,171	1,530
Shares available for sale under employee stock purchase plan	799	608
Total shares of common stock issued and reserved for issuance	<u>32,944</u>	<u>25,582</u>

#### Common Stock Warrants

The following tables summarize the Company's outstanding common stock warrants as of March 31, 2021, and December 31, 2020:

<b>March 31, 2021</b> <b>Warrants</b> <b>Outstanding</b> <b>(in thousands)</b>		<b>Exercise Price</b>	<b>Expiration Date</b>
14	\$	19.55	Dec-2022
20	\$	9.73	Aug-2023
20	\$	9.73	Mar-2024
21	\$	9.73	Dec-2024
<u>75</u>			

<b>December 31, 2020</b> <b>Warrants</b> <b>Outstanding</b> <b>(in thousands)</b>		<b>Exercise Price</b>	<b>Expiration Date</b>
14	\$	19.55	Dec-2022
30	\$	9.73	Feb-2021
20	\$	9.73	Aug-2023
20	\$	9.73	Mar-2024
21	\$	9.73	Dec-2024
<u>105</u>			

**NEURONETICS, INC.**  
**Notes to Interim Financial Statements**  
**(Unaudited)**

**14. LOSS PER SHARE**

The Company's basic loss per common share is computed by dividing the net loss by the weighted-average number of shares of common stock outstanding during the period. The Company's restricted stock awards (non-vested shares) are issued and outstanding at the time of grant but are excluded from the Company's computation of weighted-average shares outstanding in the determination of basic loss per share until vesting occurs.

A net loss cannot be diluted, so when the Company is in a net loss position, basic and diluted loss per common share are the same. If in the future the Company achieves profitability, the denominator of a diluted earnings per common share calculation will include both the weighted-average number of shares outstanding and the number of common stock equivalents, if the inclusion of such common stock equivalents would be dilutive. Dilutive common stock equivalents potentially include warrants, stock options, non-vested restricted stock units and non-vested performance restricted stock units using the treasury stock method, along with the effect, if any, from the potential conversion of outstanding securities, such as convertible preferred stock.

The following potentially dilutive securities outstanding as of March 31, 2021 and 2020 have been excluded from the denominator of the diluted loss per share of common stock outstanding calculation (in thousands):

	<u>March 31,</u>	
	<u>2021</u>	<u>2020</u>
Stock options	1,806	2,324
Non-vested performance restricted stock units	395	—
Non-vested restricted stock units	1,942	1,522
Common stock warrants	75	105

**15. SHARE-BASED COMPENSATION**

The amount of share-based compensation expense recognized by the Company by location in its statements of operations for the three months ended March 31, 2021 and 2020 is as follows (in thousands):

	<u>Three Months Ended March 31,</u>	
	<u>2021</u>	<u>2020</u>
Cost of revenues	\$ 20	\$ 16
Sales and marketing	575	430
General and administrative	1,518	607
Research and development	83	143
Total	<u>\$ 2,196</u>	<u>\$ 1,196</u>

**2018 Equity Incentive Plan**

In June 2018, the Company adopted the 2018 Equity Incentive Plan, or 2018 Plan, which authorized the issuance of up to 1.4 million shares, subject to an annual 4% increase based on the number of shares of common stock outstanding, in the form of restricted stock, stock appreciation rights and stock options to the Company's directors, employees and consultants. The amount and terms of grants are determined by the Company's board of directors. All stock options granted to date have had exercise prices equal to the fair value, as determined by the closing price as reported by the Nasdaq Global Market, of the underlying common stock on the date of grant. The contractual term of stock options is up to 10 years, and stock options are exercisable in cash or as otherwise determined by the board of directors. Generally, stock options vest 25% upon the first anniversary of the date of grant and the remainder ratably monthly thereafter for 36 months. Restricted stock units generally vest ratably in three equal installments on the first, second and third anniversaries of the grant date. Performance restricted stock units ("PRSUs") generally vest based on appreciation of the Company's common stock to a certain price as determined by the Company's board of

**NEURONETICS, INC.**  
**Notes to Interim Financial Statements**  
**(Unaudited)**

directors measured using a trailing 30-day volume weighted average price of a share of the Company's common stock. The fair value of the PRSU awards are determined using a risk neutral Monte Carlo simulation valuation model. As of March 31, 2021, there were 2.1 million shares available for future issuance under the 2018 Plan.

### 2020 Inducement Incentive Plan

In December 2020, the Company adopted the 2020 Inducement Incentive Plan, which authorized the issuance of up to 0.4 million shares in the form of stock options, stock appreciation rights, restricted stock awards, restricted stock unit awards, performance stock awards and other stock awards to eligible employees who satisfy the standards for inducement grants under Nasdaq global market rules. An individual who previously served as an employee or director of the Company is not eligible to receive awards under this plan. The amount and terms of grants are determined by the Company's board of directors. As of March 31, 2021, there were 0.1 million shares available for future issuance under the 2020 Inducement Incentive Plan.

### Stock Options

The following table summarizes the Company's stock option activity for the three months ended March 31, 2021:

	Number of Shares under Option (in thousands)	Weighted- average Exercise Price per Option	Weighted- Remaining Contractual Life (in years)	Aggregate average Intrinsic Value (in thousands)
Outstanding at December 31, 2020	2,365	\$ 4.62		
Granted	—	\$ —		
Exercised	(504)	\$ 3.67		
Forfeited	(55)	\$ 13.65		
Outstanding at March 31, 2021	<u>1,806</u>	\$ 4.73	7.6	\$ 14,544
Exercisable at March 31, 2021	<u>608</u>	\$ 7.17	4.6	\$ 3,662
Vested and expected to vest at March 31, 2021	<u>1,806</u>	\$ 4.73	7.6	\$ 14,544

The Company recognized share-based compensation expense related to stock options of \$0.2 million and \$0.6 million for the three months ended March 31, 2021 and 2020, respectively. As of March 31, 2021, there was \$2.0 million of total unrecognized compensation cost related to non-vested stock options which the Company expects to recognize over a weighted-average period of 2.6 years. The total intrinsic value of stock options exercised during the three months ended March 31, 2021 was \$6.5 million.

**NEURONETICS, INC.**  
**Notes to Interim Financial Statements**  
**(Unaudited)**

**Restricted Stock Units and Performance Restricted Stock Units**

The following table summarizes the Company's restricted stock unit and performance restricted stock unit activity for the three months ended March 31, 2021:

	Non-vested Restricted Stock Units (in thousands)	Weighted- average Grant-date Fair Value	Non-vested Performance Restricted Stock Units (in thousands)	Weighted- average Grant-date Fair Value
Non-vested at December 31, 2020	1,860	\$ 3.58	500	\$ 1.71
Granted	555	\$ 13.56	145	\$ 15.59
Vested	(322)	\$ 3.89	(250)	\$ 1.77
Forfeited	(151)	\$ 5.36	—	\$ —
Non-vested at March 31, 2021	<u>1,942</u>	<u>\$ 6.24</u>	<u>395</u>	<u>\$ 6.77</u>

The Company recognized \$1.9 million and \$0.6 million in share-based compensation expense related to the restricted stock units and performance restricted stock units for the three months ended March 31, 2021 and 2020, respectively. As of March 31, 2021, there was \$12.4 million of unrecognized compensation cost related to non-vested restricted stock units and performance restricted stock units, which the Company expects to recognize over a weighted-average period of 2.4 years. The total fair value at the vesting date of restricted stock units and performance restricted stock units vested during the three months ended March 31, 2021, was \$8.2 million.

For the period ended March 31, 2021 and December 31, 2021, the grant-date fair value of the performance restricted stock units was estimated at the time of grant using the following inputs and assumptions in the Monte Carlo simulation valuation model:

	March 31, 2021	December 31, 2020
Closing price of common stock	\$ 15.92	\$ 1.98
Risk-free interest rate	1.15 %	0.63 %
Expected volatility	99.7 %	87.4 %

**16. COMMITMENTS AND CONTINGENCIES**

**Legal Matters**

The Company is subject from time to time to various claims and legal actions arising during the ordinary course of its business. Management believes that there are currently no claims or legal actions that would reasonably be expected to have a material adverse effect on the Company's results of operations, financial condition, or cash flows.

**17. GEOGRAPHICAL SEGMENT INFORMATION**

Operating segments are defined as components of an enterprise about which separate discrete information is available for evaluation by the chief operating decision maker, or decision-making group, in deciding how to allocate resources and in assessing performance. The Company currently operates in one business segment as it is managed and operated as one business. A single management team that reports to the chief operating decision maker comprehensively manages the entire business. The Company does not operate any material separate lines of business or separate business entities with respect to its products or product development.

**NEURONETICS, INC.**  
**Notes to Interim Financial Statements**  
**(Unaudited)**

The following geographic data includes revenue generated from the Company's third-party distributors. The Company's revenue was generated in the following geographic regions and by product line for the periods indicated (in thousands):

<b>Revenues by Geography</b>				
<b>Three Months Ended March 31,</b>				
<b>2021</b>			<b>2020</b>	
	<b>Amount</b>	<b>% of Revenues</b>	<b>Amount</b>	<b>% of Revenues</b>
United States	\$ 11,802	96% %	\$ 11,177	97 %
International	486	4% %	299	3 %
<b>Total revenues</b>	<b>\$ 12,288</b>	<b>100% %</b>	<b>\$ 11,476</b>	<b>100 %</b>

<b>U.S. Revenues by Product Category</b>				
<b>Three Months Ended March 31,</b>				
<b>2021</b>			<b>2020</b>	
	<b>Amount</b>	<b>% of Revenues</b>	<b>Amount</b>	<b>% of Revenues</b>
<i>(in thousands, except percentages)</i>				
NeuroStar Advanced Therapy System	\$ 1,755	15 %	\$ 2,594	23 %
Treatment sessions	9,629	82 %	8,193	74 %
Other	418	3 %	390	3 %
<b>Total U.S. revenues</b>	<b>\$ 11,802</b>	<b>100 %</b>	<b>\$ 11,177</b>	<b>100 %</b>

<b>International Revenues by Product Category</b>				
<b>Three Months Ended March 31,</b>				
<b>2021</b>			<b>2020</b>	
	<b>Amount</b>	<b>% of Revenues</b>	<b>Amount</b>	<b>% of Revenues</b>
<i>(in thousands, except percentages)</i>				
NeuroStar Advanced Therapy System	\$ 207	43 %	\$ 100	33 %
Treatment sessions	131	27 %	77	26 %
Other	148	30 %	122	41 %
<b>Total International revenues</b>	<b>\$ 486</b>	<b>100 %</b>	<b>\$ 299</b>	<b>100 %</b>

**18. SEVERANCE**

The Company entered into transition agreements outlining the separation with its former chief executive officer in March 2020, the vice president of medical operations in September 2020, the chief commercial officer and director of medical operations in December 2020, the VP of sales and five business development managers in January 2021 and the director of strategic clinical development in February 2021. In connection with these agreements the company recorded \$0.2 million and \$1.1 million of charges in salary, payroll tax and bonus expenses in the three months ended March 31, 2021 and March 31, 2020, respectively. For the three months ended March 31, 2021 and March 31, 2020, \$0.5 million and \$0.05 million of termination benefits were paid associated with the termination of the employees and charged against this liability. As of March 31, 2021 and December 31, 2020, \$0.7 million and \$1.0 million, respectively, remain in accrued liabilities for the unpaid portion of the separation benefits.

## **Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations.**

*The following discussion and analysis of our financial condition and results of operations, as well as other sections in this Quarterly Report on Form 10-Q, should be read in conjunction with our unaudited interim financial statements and related notes thereto included elsewhere herein. In addition to historical financial information, some of the information contained in the following discussion and analysis contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements other than statements of historical facts, including statements regarding our future results of operations and financial position, business strategy, current and prospective products, product approvals, research and development costs, current and prospective collaborations, timing and likelihood of success, plans and objectives of management for future operations and future results of current and anticipated products, are forward-looking statements. These statements involve known and unknown risks, uncertainties, assumptions and other important factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. These risks and uncertainties include, without limitation, risks and uncertainties related to: the ongoing impact of the novel coronavirus, or COVID-19, pandemic on general political and economic uncertainty, including as a result of efforts by governmental authorities to mitigate the COVID-19 pandemic, such as travel bans, shelter in place orders and third-party business closures and the related impact on resource allocations, manufacturing and supply chains and patient access to commercial products; our ability to execute our business continuity as well as our operational and budget plans in light of the COVID-19 pandemic; our ability to achieve or sustain profitable operations due to our history of losses; our reliance on the sale and usage of our NeuroStar Advanced Therapy System to generate revenues; the scale and efficacy of our salesforce; availability of coverage and reimbursement from third-party payors for treatments using our products; physician and patient demand for treatments using our products; developments in respect of competing technologies and therapies for the indications that our products treat; product defects; our ability to obtain and maintain intellectual property protection for our technology; developments in clinical trials or regulatory review of NeuroStar Advanced Therapy System for additional indications; and developments in regulation in the United States and other applicable jurisdictions. For a discussion of these and other related risks, please refer to our recent SEC filings which are available on the SEC's website at [www.sec.gov](http://www.sec.gov). These forward-looking statements are based on our expectations and assumptions as of the date of this Quarterly Report on Form 10-Q. Except as required by law, we undertake no duty or obligation to update any forward-looking statements contained in this Quarterly Report on Form 10-Q as a result of new information, future events or changes in our expectations.*

*In some cases, you can identify forward-looking statements by terms such as "may," "will," "should," "expect," "plan," "anticipate," "could," "intend," "target," "project," "contemplates," "believes," "estimates," "predicts," "potential" or "continue" or the negative of these terms or other similar expressions. The forward-looking statements in this Quarterly Report on Form 10-Q are only predictions. We have based these forward-looking statements largely on our current expectations and projections about future events and financial trends that we believe may affect our business, financial condition and results of operations. These forward-looking statements speak only as of the date of this Quarterly Report on Form 10-Q and are subject to a number of risks, uncertainties and assumptions described in "Risk Factors" and "Management's Discussion and Analysis of Financial Condition and Results of Operations" in our Annual Report on Form 10-K filed with the SEC, on March 2, 2021. The events and circumstances reflected in our forward-looking statements may not be achieved or occur and actual results could differ materially from those projected in the forward-looking statements. Moreover, we operate in an evolving environment. New risk factors and uncertainties may emerge from time to time, and it is not possible for us to predict all risk factors and uncertainties. Except as required by applicable law, we do not plan to publicly update or revise any forward-looking statements contained herein, whether as a result of any new information, future events, changed circumstances or otherwise.*

## Overview

We are a commercial stage medical technology company focused on designing, developing and marketing products that improve the quality of life for patients who suffer from psychiatric disorders. Our first commercial product, the NeuroStar® Advanced Therapy System, is a non-invasive and non-systemic office-based treatment that uses transcranial magnetic stimulation, or TMS, to create a pulsed, MRI-strength magnetic field that induces electrical currents designed to stimulate specific areas of the brain associated with mood. The system is cleared by the United States Food and Drug Administration, or FDA, to treat adult patients with major depressive disorder, or MDD, that have failed to achieve satisfactory improvement from prior antidepressant medication in the current MDD episode. NeuroStar Advanced Therapy is also available in other parts of the world, including Japan, where it is listed under Japan's national health insurance. NeuroStar Advanced Therapy is safe, clinically effective, reproducible and precise and we believe is supported by the largest clinical data set of any competing TMS system. We are the market leader in TMS therapy based on the estimated 112,000 global patients treated with approximately 4.0 million of our treatment sessions through such date. We generated revenues of \$12.3 million and \$11.5 million for the three months ended March 31, 2021 and 2020, respectively.

We designed the NeuroStar Advanced Therapy System as a non-invasive therapeutic alternative to treat patients who suffer from MDD and to address many of the key limitations of other treatment options. We generate revenues from initial capital sales of our systems, recurring Treatment Sessions and service and repair and extended warranty contracts. We derive the majority of our revenues from recurring Treatment Sessions. For the three months ended March 31, 2021, revenues from sales of our Treatment Sessions and NeuroStar Advanced Therapy Systems represented 81.6% and 14.9% of our U.S. revenues, respectively.

We currently sell our NeuroStar Advanced Therapy System and recurring Treatment Sessions in the United States with the collaborative support of our 147 employees as of March 31, 2021. Our sales force targets an estimated 50,000 psychiatrists across 26,000 psychiatric practices in the United States, based on data from Symphony Health and our own internal estimates that treat approximately 42% of the total MDD patients in the United States who meet our labeled indication and are insured. Some of our customers have and may purchase more than one NeuroStar Advanced Therapy System. Based on our commercial data, on average, we believe our customers can recoup their initial capital investment in our system by providing a standard course of treatment to approximately 12 patients. We believe psychiatrists can generate approximately \$7,500 to \$10,000 of revenue per patient for a standard course of treatment, which may provide meaningful incremental income to their practices. We have a diverse customer base of psychiatrists in group psychiatric practices in the United States. For the three months ended March 31, 2021, one customer accounted for more than 10% of our revenues.

We market our products in a few select markets outside the United States through independent distributors. International revenues represented 4.0% and 3.0% of our total revenues for the three months ended March 31, 2021 and 2020, respectively. In October 2017, we entered into an exclusive distribution agreement with Teijin Pharma Limited, or Teijin, for the distribution of our NeuroStar Advanced Therapy Systems and Treatment Sessions to customers who will treat patients with MDD in Japan. We received regulatory approval for our system in Japan in September 2017 and we received the initial reimbursement of JPY 12,000 per Treatment Session, which went into effect on June 1, 2019. We expect our international revenues to increase over time as a percentage of our total revenues as we grow system placements and utilization in Japan.

Our research and development efforts are focused on the following: hardware and software product developments and enhancements of our NeuroStar Advanced Therapy System and clinical development relating to expansion of our label and additional indications, which may include bipolar depression and post-traumatic stress disorder. We outsource the manufacture of components of our NeuroStar Advanced Therapy Systems that are produced to our specifications, and individual components are either shipped directly from our third-party contract manufacturers to our customers or consolidated into pallets at our Malvern, Pennsylvania facility prior to shipment. Final installation of these systems occurs at the customer site.

Our total revenues increased by \$0.8 million, or 7%, from \$11.5 million for the three months ended March 31, 2020 to \$12.3 million for the three months ended March 31, 2021. For the three months ended March 31, 2021, our U.S. revenues were \$11.8 million compared to \$11.2 million for the three months ended March 31, 2020, which represents an increase of 6% over the prior year quarter. The increase was primarily attributable to an increase in U.S. treatment session revenue over the prior year quarter. We incurred net losses of \$7.9 million for the three months ended March 31, 2021 compared to net losses of \$12.6 million for the three months ended March 31, 2020. We expect to continue to incur losses for the next several years as we invest in our commercial organization to support our planned sales growth and while continuing to invest in our pipeline indications. As of March 31, 2021, we had an accumulated deficit of \$285.4 million.

### **COVID-19**

Throughout 2020 and the three months ended March 31, 2021, the Company experienced a material impact to revenue, particularly with regards to U.S. treatment session revenues as a result of the COVID-19 pandemic. The Company expects that capital equipment sales and treatment session revenues will continue to be materially impacted by this pandemic as customers are deferring capital purchase decisions and new patient treatment starts. System utilization has also declined compared to pre-COVID-19 projections.

We have monitored the impact of the COVID-19 pandemic on all aspects of our business and geographies, including how it has and will continue to impact the Company's customers, supply chain, employees and other business partners. While we experienced significant disruptions in 2020 and the three months ended March 31, 2021 from the COVID-19 pandemic, we are unable to predict the impact that the COVID-19 pandemic may have on financial condition, results of operations and cash flows due to numerous uncertainties. These uncertainties include the scope, severity and duration of the ongoing pandemic, the actions taken to contain the pandemic or mitigate its impact and the direct and indirect economic effects of the pandemic and containment measures, among others. The outbreak of COVID-19 in many countries, including the United States, has significantly adversely impacted global economic activity.

The situation surrounding the COVID-19 pandemic remains fluid, and we are actively managing our response in collaboration with business partners and assessing potential impacts to our financial position and operating results, as well as potential adverse developments in our business. For further information regarding the impact of COVID-19 on the Company, see Part II, Item 1A titled "Risk Factors" of our Quarterly Report on Form 10-Q for the period ended March 31, 2021.

### **Components of Our Results of Operations**

#### *Revenues*

To date, we have generated revenues primarily from the capital portion of our business and related sales and rentals of the NeuroStar Advanced Therapy System and the recurring revenues from our sale of treatment sessions in the United States.

**NeuroStar Advanced Therapy System Revenues.** NeuroStar Advanced Therapy System revenues consist primarily of sales or rentals of a capital component, including upgrades to the equipment attributable to the initial sale of the system. NeuroStar Advanced Therapy Systems can be purchased outright or on a rent-to-own basis by certain customers.

**Treatment Session Revenues.** Treatment session revenues primarily include sales of NeuroStar Treatment Sessions and SenStar treatment links. The NeuroStar Treatment Sessions are access codes that are delivered electronically in the United States. The SenStar treatment links are disposable units containing single-use access codes that are sold and used outside the United States. Access codes are purchased separately by our customers, primarily on an as-needed basis, and are required by the NeuroStar Advanced Therapy System in order to deliver treatment sessions.

**Other Revenues.** Other revenues are derived primarily from service and repair and extended warranty contracts with our existing customers.

We refer you to the section titled “Critical Accounting Policies and Use of Estimates—Revenue Recognition” appearing in our Form 10-K filed with the SEC on March 2, 2021. We also refer you to “Note 3. Summary of Significant Accounting Policies.”

#### *Cost of Revenues and Gross Margin*

Cost of revenues primarily consists of the costs of components and products purchased from our third-party contract manufacturers of our NeuroStar Advanced Therapy Systems as well as the cost of treatment packs for individual treatment sessions. We use third-party contract manufacturing partners to produce the components for and assemble the completed NeuroStar Advanced Therapy Systems. Cost of revenues also includes costs related to personnel, royalties, warranty, shipping, and our operations and field service departments. We expect our cost of revenues to increase in absolute dollars as and to the extent our revenues grow.

Our gross profit is calculated by subtracting our cost of revenues from our revenues. We calculate our gross margin as our gross profit divided by our revenues. Our gross margin has been and will continue to be affected by a variety of factors, primarily product sales mix, pricing and third-party contract manufacturing costs. Our gross margins on revenues from sales of NeuroStar Advanced Therapy Systems are lower than our gross margins on revenues from sales of treatment sessions and, as a result, the sales mix between NeuroStar Advanced Therapy Systems and treatment sessions can affect the gross margin in any reporting period.

#### *Sales and Marketing Expenses*

Sales and marketing expenses consist of market research and commercial activities related to the sale of our NeuroStar Advanced Therapy Systems and treatment sessions and salaries and related benefits, sales commissions and share-based compensation for employees focused on these efforts. Other significant sales and marketing costs included conferences and trade shows, promotional and marketing activities, including direct and online marketing, practice support programs, travel and training expenses.

We anticipate that our sales and marketing expenses will increase as we continue to execute on our growth initiatives and expand our business in the United States.

#### *General and Administrative Expenses*

General and administrative expenses consist primarily of personnel expenses, including salaries and related benefits, share-based compensation and travel expenses, for employees in executive, finance, information technology, legal and human resource functions. General and administrative expenses also include the cost of insurance, outside legal fees, accounting and other consulting services, audit fees from our independent registered public accounting firm, board of directors' fees and other administrative costs, such as corporate facility costs, including rent, utilities, depreciation and maintenance not otherwise included in cost of revenues.

We anticipate that our general and administrative expenses will increase in fiscal year 2021 from fiscal year 2020.

#### *Research and Development Expenses*

Research and development expenses consist primarily of personnel expenses, including salaries and related benefits and share-based compensation for employees in clinical development, product development, regulatory and quality assurance functions, as well as expenses associated with outsourced professional scientific development services and costs of investigative sites and consultants that conduct our preclinical

and clinical development programs. We typically use our employee, consultant and infrastructure resources across our research and development programs.

We plan to incur research and development expenses for the near future as we expect to continue our development of TMS Therapy for the treatment of additional patient populations and new indications, which may include bipolar depression, post-traumatic stress disorder and potential other clinical indications yet to be determined, as well as for various hardware and software development projects. As a result, we expect our research and development expenses to remain similar to our fiscal year 2020 expenses.

*Interest Expense*

Interest expense consists of cash interest payable under our credit facility and non-cash interest attributable to the accrual of final payment fees and the amortization of deferred financing costs related to our indebtedness.

*Other Income, Net*

Other income, net consists primarily of interest income earned on our money market account balances.

**Results of Operations**

**Comparison of the Three Months ended March 31, 2021 and 2020**

	Three Months Ended March 31,		Increase / (Decrease)	
	2021	2020	Dollars	Percentage
	(in thousands, except percentages)			
Revenues	\$ 12,288	\$ 11,476	\$ 812	7 %
Cost of revenues	2,221	2,811	(590)	(21)%
Gross Profit	10,067	8,665	1,402	16 %
Gross Margin	81.9 %	75.5 %		
Operating expenses:				
Sales and marketing	8,561	10,723	(2,162)	(20)%
General and administrative	6,104	5,287	817	15 %
Research and development	2,311	3,021	(710)	(24)%
Total operating expenses	16,976	19,031	(2,055)	(11)%
Loss from Operations	(6,909)	(10,366)	3,457	33 %
Other (income) expense:				
Interest expense	985	1,523	(538)	(35)%
Loss on extinguishment of debt	—	924	(924)	100 %
Other income, net	(13)	(200)	187	(94)%
Net Loss	\$ (7,881)	\$ (12,613)	\$ 4,732	38 %

	Revenues by Geography			
	Three Months Ended March 31,			
	2021		2020	
	Amount	% of Revenues	Amount	% of Revenues
	(in thousands, except percentages)			
United States	\$ 11,802	96 %	\$ 11,177	97 %
International	486	4 %	299	3 %
Total revenues	\$ 12,288	100 %	\$ 11,476	100 %

U.S. Revenues by Product Category				
Three Months Ended March 31,				
	2021		2020	
	Amount	% of Revenues	Amount	% of Revenues
(in thousands, except percentages)				
NeuroStar Advanced Therapy System	\$ 1,755	15 %	\$ 2,594	23 %
Treatment sessions	9,629	82 %	8,193	73 %
Other	418	3 %	390	3 %
Total U.S. revenues	<u>\$ 11,802</u>	<u>100 %</u>	<u>\$ 11,177</u>	<u>100 %</u>

United States NeuroStar Advanced Therapy System				
Revenues by Type				
Three Months Ended March 31,				
	2021		2020	
	Amount	% of Revenues	Amount	% of Revenues
(in thousands, except percentages)				
NeuroStar Capital	\$ 1,589	91 %	\$ 2,410	93 %
Operating lease	108	6 %	155	6 %
Other	58	3 %	29	1 %
Total United States NeuroStar Advanced Therapy System revenues	<u>\$ 1,755</u>	<u>100 %</u>	<u>\$ 2,594</u>	<u>100 %</u>

### Revenues

Total revenue for the three months ended March 31, 2021 was \$12.3 million, an increase of 7% compared to the three months ended March 31, 2020 revenue of \$11.5 million. During the quarter, total U.S. revenue increased by 6% and international revenue increased by 63% over the prior year quarter. The U.S. revenue growth was driven by an increase in U.S. treatment session revenue and the International revenue growth was driven by an increase in NeuroStar Advanced Therapy System sales.

U.S. NeuroStar Advanced Therapy System revenue for the three months ended March 31, 2021 was \$1.8 million, a decrease of 32% compared to the three months ended March 31, 2020 revenue of \$2.6 million. The decrease was primarily driven by a lower number of NeuroStar systems sold in the three months ended March 31, 2021, which was partially offset by an increase in the blended NeuroStar system average selling price quarter over quarter. For the three months ended March 31, 2021 and 2020, the Company sold 23 and 38 systems, respectively, during each period.

U.S. treatment session revenue for the three months ended March 31, 2021 was \$9.6 million, an increase of 18% compared to the three months ended March 31, 2020 revenue of \$8.2 million. The revenue growth was primarily driven by an increase in per click treatment session volume quarter over quarter.

### Cost of Revenues and Gross Margin

Cost of revenues decreased by \$0.6 million or 21% from \$2.8 million for the three months ended March 31, 2020 to \$2.2 million for the three months ended March 31, 2021. Gross margin increased from 75.5% for the three months ended March 31, 2020 to 81.9% for the three months ended March 31, 2021. The increase was primarily a result of a change in the product mix of revenues versus the prior year quarter.

### Sales and Marketing Expenses

Sales and marketing expenses decreased by \$2.1 million, or 20%, from \$10.7 million for the three months ended March 31, 2020 to \$8.6 million for the three months ended March 31, 2021. The decrease was primarily due to reduced sales, reimbursement and clinical training costs versus the prior year quarter.

### *General and Administrative Expenses*

General and administrative expenses increased by \$0.8 million, or 15%, from \$5.3 million for the three months ended March 31, 2020 to \$6.1 million for the three months ended March 31, 2021. The increase was primarily due to an increase in personnel expenses related to bonus, salary and share based compensation.

### *Research and Development Expenses*

Research and development expenses decreased \$0.7 million, or 24%, from \$3.0 million for the three months ended March 31, 2020 to \$2.3 million for the three months ended March 31, 2021. The decrease was primarily due to reduced product development, personnel and travel expenses.

### *Interest Expense*

Interest expense decreased \$0.5 million, or 35% from \$1.5 million for the three months ended March 31, 2020 to \$1.0 million for the three months ended March 31, 2021. The decrease in interest expense was due to the loss on extinguishment of debt charge recognized in the first quarter of 2020 as part of Oxford debt facility. Refer to "Note 12. Debt" in the financial statements included in this Quarterly Report on Form 10-Q for information regarding the Oxford debt facility.

### *Other Income, Net*

Other income, net decreased by \$0.2 million, from \$0.2 million for the three months ended March 31, 2020 to \$0.0 million for the three months ended March 31, 2021, primarily as a result of decreased interest income earned on the Company's money market accounts.

## **Liquidity and Capital Resources**

### *Overview*

On February 2, 2021, we closed on the Offering of our common stock in which we issued and sold 5,566,000 shares of our common stock, which included shares pursuant to an option granted to underwriters to purchase additional shares, at a public offering price of \$15.50 per share. We received net proceeds of \$80.6 million after deducting underwriting discounts, commissions and offering expenses.

As of March 31, 2021, we had cash and cash equivalents of \$121.3 million and an accumulated deficit of \$285.4 million, compared to cash and cash equivalents of \$49.0 million and an accumulated deficit of \$277.5 million as of December 31, 2020. We incurred negative cash flows from operating activities of \$9.2 million and \$13.7 million for the three months ended March 31, 2021 and 2020, respectively. We have incurred operating losses since our inception, and we anticipate that our operating losses will continue in the near term as we seek to expand our sales and marketing initiatives to support our growth in existing and new markets, invest funds in additional research and development activities and utilize cash for other corporate purposes. Our primary sources of capital to date have been from our IPO, private placements of our convertible preferred securities, borrowings under our credit facilities, sales of our products and other public offerings of our common stock. As of March 31, 2021, the Company had \$35.0 million of borrowings outstanding under its credit facility, which has a final maturity in February 2025. Management believes that the Company's cash and cash equivalents as of March 31, 2021 and anticipated revenues from sales of its products are sufficient to fund the Company's operations for at least 12 months from the issuance of these financial statements.

We cannot predict our revenues and expenses in the short term, in large part due to uncertainty relating the COVID-19 pandemic and related governmental responses. However, if our cash and cash equivalents and anticipated revenues from sales of our products are insufficient to satisfy our liquidity requirements, we may seek to sell additional common or preferred equity or debt securities or enter into a new credit facility or another form of third-party funding or seek other debt financing. If we raise additional funds by issuing equity

or equity-linked securities, our stockholders would experience dilution and any new equity securities could have rights, preferences and privileges superior to those of holders of our common stock. Debt financing, if available, may involve covenants restricting our operations or our ability to incur additional debt. We cannot be assured that additional equity, equity-linked or debt financing will be available on terms favorable to us or our stockholders, or at all. It is also possible that we may allocate significant amounts of capital towards products or technologies for which market demand is lower than expected and, as a result, abandon such efforts. If we are unable to maintain our current financing or obtain adequate additional financing when we require it, or if we obtain financing on terms which are not favorable to us, or if we expend capital on products or technologies that are unsuccessful, our ability to continue to support our business growth and to respond to business challenges could be significantly limited, or we may be required to delay the development, commercialization and marketing of our products.

Our current and future funding requirements will depend on many factors, including:

- the impact of COVID-19 and related governmental responses;
- our ability to achieve revenue growth and improve operating margins;
- compliance with the terms and conditions, including covenants, set forth in our credit facility;
- the cost of expanding our operations and offerings, including our sales and marketing efforts;
- our ability to improve or maintain coverage and reimbursement arrangements with domestic third-party and government payors, particularly in Japan;
- our rate of progress in establishing coverage and reimbursement arrangements from international commercial third-party and government payors;
- our rate of progress in, and cost of the sales and marketing activities associated with, establishing adoption of our products and maintaining or improving our sales to our current customers;
- the cost of research and development activities, including research and development relating to additional indications, which may include bipolar depression;
- the effect of competing technological and market developments;
- costs related to international expansion; and
- the potential cost of and delays in product development as a result of any regulatory oversight applicable to our products.

#### *Cash Flows*

The following table sets forth a summary of our cash flows for the three months ended March 31, 2021 and March 31, 2020:

	<b>Three Months Ended March 31,</b>	
	<b>2021</b>	<b>2020</b>
	<b>(in thousands)</b>	
Net Cash Used in Operating Activities	\$ (9,168)	\$ (13,650)
Net Cash Used in Investing Activities	(675)	(266)
Net Cash Provided by Financing Activities	82,163	1,855
Net Increase (Decrease) in Cash and Cash Equivalents	<u>\$ 72,320</u>	<u>\$ (12,061)</u>

*Net Cash Used in Operating Activities*

Net cash used in operating activities for the three months ended March 31, 2021 was \$9.2 million, consisting primarily of a net loss of \$7.9 million and a decrease in net operating liabilities of \$4.0 million, partially offset by non-cash charges of \$2.7 million. The decrease in net operating liabilities was primarily due to an increase in inventory and decreases in accounts payable and accrued expenses as a result of timing and the 2021 payment of the 2020 bonus compensation accrued as of December 31, 2020. Non-cash charges consisted of depreciation and amortization, non-cash interest expense, share-based compensation, and the cost of rental units purchased by customers.

Net cash used in operating activities for the three months ended March 31, 2020 was \$13.7 million, consisting primarily of a net loss of \$12.6 million and a decrease in net operating liabilities of \$4.0 million, partially offset by non-cash charges of 3.0 million. The decrease in net operating liabilities was primarily due to decreases in accounts payable and accrued expenses as a result of timing and the first quarter 2020 payments of 2019 incentive compensation and commissions accrued as of December 31, 2019. Non-cash charges consisted of loss on debt extinguishment, depreciation and amortization, non-cash interest expense, share-based compensation, and the cost of rental units purchased by customers.

*Net Cash Used in Investing Activities*

Net cash used in investing activities for the three months ended March 31, 2021 and the three months ended March 31, 2020 was \$0.7 million and \$0.3 million, respectively. Each was attributable to purchases of property and equipment and capitalized software costs.

*Net Cash Provided by Financing Activities*

Net cash provided by financing activities for the three months ended March 31, 2021 was \$82.2 million and primarily consisted of additional proceeds from our Offering and cash proceeds related to stock option exercises. Net cash provided by financing activities for the three months ended March 31, 2020 was \$1.9 million and consisted of additional proceeds from our loan refinance and cash proceeds related to stock option exercises.

**Indebtedness**

**Solar Credit Facility**

On March 2, 2020, the "Company entered into a loan and security agreement with Solar Capital Ltd., or Solar, as collateral agent, and other lenders defined in the agreement, for a credit facility, or the Solar Facility, that replaced the Company's previous \$35.0 million credit facility with Oxford Finance LLC, or Oxford, and such facility, the Oxford Facility.

The Solar Facility permits the Company to borrow up to an aggregate amount of \$50.0 million in two tranches of term loans, a "Term A Loan" and "Term B Loan." On March 2, 2020, the Company borrowed an aggregate amount of \$35.0 million, which was the aggregate amount available under the Term A Loan portion of the Solar Facility. The Term A Loan portion of the Solar Facility matures, and all amounts borrowed thereunder are due, on February 28, 2025. Under the Term B Loan portion of the Solar Facility, the Company is permitted to borrow, at its election, up to an aggregate amount of \$15.0 million, (i) upon the Company achieving a specified amount of trailing twelve months net product revenue, and (ii) assuming there has been no event of default under the Solar Facility prior to such election. Once the net product revenue condition has been satisfied, the Company may only make an election to borrow under the Term B Loan portion of the Solar Facility until the earlier of (a) December 15, 2021, (b) 30 days following achievement of the net product revenue condition or (c) the occurrence of an event of default.

Each of the Term A Loan and Term B Loan accrue interest from the date of borrowing through the date of repayment at a floating per annum rate of interest, which resets monthly and is equal to 7.65% plus the greater of (a) 1.66% or (b) the rate per annum rate published by the Intercontinental Exchange Benchmark Administration Ltd. The Term A Loan and the Term B Loan both include an interest-only period through March 1, 2022, after which time the Company will be required to make monthly payments of principal and interest. Monthly principal payments are to be paid in equal amounts on a pro rata basis to lenders. At the Company's election, the interest only period may be extended through February 2023 if the Company satisfies a minimum net product revenue covenant through March 1, 2022 and no event of default shall have occurred.

In addition to the principal and interest payments due under the Solar Facility, the Company is required to pay a final payment fee to Solar due upon the earlier of prepayment, acceleration or the maturity date of the Term A Loan or Term B Loan portion of the Solar Facility equal to 5.50% of the principal amount of the term loans actually funded. The Company is accruing the final payment fees using the effective interest rate, with a charge to non-cash interest expense, over the term of borrowing. If the Company prepays either the of the Term A Loan or Term B Loan prior to their respective scheduled maturities, the Company will also be required to pay prepayment fees to Solar equal to 3% of the principal amount of such term loan then-prepaid if prepaid on or before the first anniversary of funding, 2% of the principal amount of such term loan then-prepaid if prepaid after the first anniversary and on or before the second anniversary of funding, or 1% of the principal amount of such term loan then-prepaid if prepaid after the second anniversary of funding of the principal amounts borrowed.

The Company is also required to pay Solar an exit fee upon the occurrence, prior to March 2, 2030, of (a) any liquidation, dissolution or winding up of the Company, (b) transaction that results in a person obtaining control over the Company, (c) the Company achieving \$100 million in trailing twelve month net product revenue or (d) the Company achieving \$125 million in trailing twelve month net product revenue. The exit fee for liquidation, dissolution, winding up or change of control of the Company is equal to 4.50% of the principal amount of the term loans actually funded. The exit fee for achieving either \$100 million or \$125 million in trailing twelve-month net product revenue is equal to 2.25% of the principal amount of the term loans actually funded or, if both net product revenue milestones are achieved, 4.50% of the principal amount of the term loans actually funded. The exit fee is capped at 4.50% of the principal amount of the term loans actually funded.

On December 8, 2020, the Company, Solar Capital Ltd., and our other lenders defined in the Solar Facility, executed an amendment to the Solar Facility (the "Solar Amendment"). The Solar Amendment divides the aggregate Term B Loan borrowing amount of \$15.0 million allowable upon our achievement of specific trailing twelve-month net product revenue targets into three separate \$5.0 million tranches ("Amended Term B Loan", "Term C Loan" and "Term D Loan"). The three tranches are available through June 20, 2021, December 20, 2021, and June 20, 2022, respectively, based on the achievement of agreed upon trailing twelve-month net product revenue targets for each tranche.

The Solar Amendment also reduces the trailing twelve-month net product revenue requirement for the Amended Term B Loan portion of the facility. Subject to certain conditions, the Company has the ability to extend the interest-only period on the initial Term A Loan to 36 months from 24 months upon achieving the revenue targets associated with the Amended Term B Loan. As of March 31, 2021, the Company is in compliance with the required minimum net product revenue covenant and anticipates electing to extend the interest-only period through March 1, 2023 for the Term A Loan, subject to continuing to meet the required conditions through and as of March 1, 2022. The Company is projected to be in compliance with the required covenant. The Company was required to pay an amendment fee of \$0.1 million to Solar, which has been recognized as a deferred debt issuance cost as of December 31, 2020 that will be amortized to interest expense using the effective interest method.

The Company's obligations under the Solar Facility are secured by a first priority security interest in substantially all of its assets, including its intellectual property. The loan and security agreement requires the Company to comply with certain financial covenants as well as customary affirmative and negative covenants.

The Solar Facility contains events of default, including, without limitation, events of default upon: (i) failure to make payment pursuant to the terms of the agreement; (ii) violation of covenants; (iii) material adverse changes to the Company's business; (iv) attachment or levy on the Company's assets or judicial restraint on its business; (v) insolvency; (vi) material cross-defaults; (vii) significant judgments, orders or decrees for payments by the Company not covered by insurance; (viii) incorrectness of representations and warranties; (ix) incurrence of subordinated debt; (x) a termination or breach of a guaranty; (xi) revocation of governmental approvals necessary for the Company to conduct its business; and (xii) failure by the Company to maintain a valid and perfected lien on the collateral securing the borrowing. The Solar Facility includes subjective acceleration clauses which permit the lenders to accelerate the maturity date under certain circumstances, including, but not limited to, material adverse effects on a Company's financial status or otherwise.

The Solar Facility includes a financial covenant requiring the attainment of a minimum trailing net revenue amount beginning on December 31, 2020. The Company and lenders executed the Solar Amendment in December 2020 that reduced the minimum trailing net revenue covenant requirement amounts beginning on December 31, 2020 to allow the Company to maintain compliance with the covenant as of December 31, 2020. As of March 31, 2021, the Company is in compliance with the financial covenant and is projected to be in compliance with the reduced minimum revenue covenant amounts going forward.

As of March 31, 2021, the Company is in compliance with all covenants in the Solar Facility.

### **Oxford Credit Facility**

Prior to March 2020, the Company had a \$35.0 million credit facility in place with Oxford, which it entered into in March 2017 and that allowed it to borrow up to \$35.0 million in three tranches of term loans: a Term A Loan in the amount of \$25 million, which was drawn immediately upon closing in March 2017, a Term B Loan in the amount of \$5.0 million, which was drawn down in December 2017, and a Term C Loan in the amount of \$5.0 million which was never drawn down. Each term loan accrued interest from the date of borrowing through the date of repayment at a floating per annum rate of interest, which reset monthly and was equal to the greater of (a) 8.15% or (b) the 30 day U.S. LIBOR on the last business day of the month plus 7.38%. This facility featured an interest-only period on all tranches through March 2019.

In addition to principal and interest payments due under the \$35.0 million Oxford credit facility, the Company was required to make final payment fees to Oxford upon the earlier of prepayment or maturity and equal to 8.5% and 7.5% of the principal amounts of the Term A and Term B Loans, respectively. The Company accrued final payment fees using the effective interest rate, with a charge to non-cash interest expense, over the term of borrowing and until its entry into the Solar credit facility in March 2020, at which time the Company paid Oxford \$2.5 million in satisfaction of all final payment fee liabilities due under the Oxford credit facility.

The Company evaluated whether the Solar credit facility entered into in March 2020 represented a debt modification or extinguishment in accordance with ASC 470-50, Debt—Modifications and Extinguishments and determined that the existing debt was extinguished as a result of the full repayment of the existing facility and concurrent issuance of a new credit facility with a new lender. The unamortized balance of the Company's combined debt discount and deferred issuance costs of \$0.6 million related to the Oxford facility were accounted for as a loss on extinguishment of debt.

### *Cash and Non-Cash Interest Expense*

For the three months ended March 31, 2021, we recognized interest expense of \$1.0 million, of which \$0.8 million was cash and \$0.2 million was non-cash interest expense related to the amortization of deferred financing costs and accrual of final payment fees. For the three months ended March 31, 2020, we

recognized interest expense of \$1.5 million, of which \$1.4 million was cash and \$0.1 million was non-cash interest expense related to the amortization of deferred financing costs and accrual of final payment fees

### **Common Stock Offering**

On February 2, 2021, we closed on our public offering and sale (the “Offering”) of our common stock in which we issued and sold 5,566,000 shares of our common stock, which included shares pursuant to an option granted to underwriters to purchase additional shares, at a public offering price of \$15.50 per share. We received net proceeds of \$80.6 million after deducting underwriting discounts, commissions and offering expenses.

### **Off-Balance Sheet Arrangements**

We do not maintain any off-balance sheet arrangements, partnerships or other relationships with unconsolidated entities, often referred to as structured finance or special-purpose entities, which are established for the purpose of facilitating off-balance sheet arrangements or other contractually narrow or limited purposes.

### **Commitments and Contractual Obligations**

As of March 31, 2021, there were no significant changes to our commitments and future minimum contractual obligations as set forth in our Form 10-K, filed with the SEC on March 2, 2021.

### **JOBS Act Accounting Election**

We are an “emerging growth company,” as defined in the Jumpstart Our Business Startups Act of 2012, or JOBS Act, and are eligible to take advantage of certain exemptions from various reporting requirements that are applicable to other public companies that are not emerging growth companies. Section 107 of the JOBS Act provides that an emerging growth company can take advantage of the extended transition period provided in Section 7(a)(2)(B) of the Securities Act of 1933, or Securities Act, for complying with new or revised accounting standards issued subsequent to the enactment of the JOBS Act until such time as those standards apply to private companies. We have elected to avail ourselves of this exemption from complying with new or revised accounting standards and, therefore, will not be subject to the same new or revised accounting standards as other public companies that are not emerging growth companies. Section 107 of the JOBS Act provides that we can elect to opt out of the extended transition period at any time, which election is irrevocable.

Subject to certain conditions, as an emerging growth company, we may rely on certain of these exemptions, including without limitation (i) providing an auditor’s attestation report on our system of internal controls over financial reporting pursuant to Section 404(b) of the Sarbanes-Oxley Act and (ii) complying with any requirement that may be adopted by the Public Company Accounting Oversight Board regarding mandatory audit firm rotation or a supplement to the auditor’s report providing additional information about the audit and the financial statements, known as the auditor discussion and analysis. We will remain an emerging growth company until the earlier of (a) the last day of the fiscal year in which we have total annual gross revenue of \$1.07 billion or more; (b) the last day of the fiscal year following the fifth anniversary of the date of the completion of this offering; (c) the date on which we have issued more than \$1.0 billion in nonconvertible debt during the previous six years; or (d) the date on which we are deemed to be a large accelerated filer under the rules of the SEC.

### **Recent Accounting Pronouncements**

We refer you to “Note 3. Summary of Significant Accounting Policies” and “Note 4. Recent Accounting Pronouncements” in “Notes to Interim Financial Statements” located in “Part I – FINANCIAL INFORMATION, Item 1. Financial Statements”.

**Item 3. Quantitative and Qualitative Disclosures About Market Risk.**

We refer you to the information described in the “Item 7A. Quantitative and Qualitative Disclosures About Market Risk” section of the Company’s Annual Report on Form 10-K filed with the SEC on March 2, 2021. There have been no material changes to our market risk described therein.

**Item 4. Controls and Procedures.**

**Evaluation of Disclosure Controls and Procedures**

The term “disclosure controls and procedures,” as defined in Rules 13a-15(e) and 15d-15(e) of the Securities Exchange Act of 1934, as amended, or Exchange Act, refers to controls and procedures that are designed to ensure that information required to be disclosed by a company in the reports that it files or submits under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the SEC’s rules and forms. Disclosure controls and procedures include, without limitation, controls and procedures designed to ensure that information required to be disclosed by a company in the reports that it files or submits under the Exchange Act is accumulated and communicated to the company’s management, including its principal executive officer and principal financial officer, as appropriate to allow timely decisions regarding required disclosure. As required by Rules 13a-15(b) and 15d-15(b) of the Exchange Act, our management, with the participation of our Principal Executive Officer and Chief Financial Officer, evaluated the effectiveness of our disclosure controls and procedures as of the end of the period covered by this Quarterly Report on Form 10-Q. Based on that evaluation, our Principal Executive Officer and our Chief Financial Officer concluded that our disclosure controls and procedures were effective at the reasonable assurance level as of March 31, 2021.

**Changes in Internal Control over Financial Reporting**

During the quarter ended March 31, 2021, there were no changes in our internal control over financial reporting (as defined in Rule 13a-15(f) of the Exchange Act) which materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

**PART II—OTHER INFORMATION**

**Item 1. Legal Proceedings.**

We are subject from time to time to various claims and legal actions arising during the ordinary course of our business. We believe that there are currently no claims or legal actions that would reasonably be expected to have a material adverse effect on our results of operations, financial condition, or cash flows.

**Item 1A. Risk Factors.**

You should carefully consider the information described in the “Risk Factors” section of the Company’s Annual Report on Form 10-K filed with the SEC on March 2, 2021. There have been no material changes to the risk factors described therein.

**Item 2. Unregistered Sales of Equity Securities and Use of Proceeds.**

Recent Issuances of Unregistered Securities

None.

**Item 3. Defaults Upon Senior Securities.**

Not applicable.

**Item 4. Mine Safety Disclosures.**

Not applicable.

**Item 5. Other Information.**

On April 28 and 29, 2021, respectively, the Compensation Committee of the Company’s Board of Directors and the Company’s Board of Directors approved modifications to the severance provisions applicable to the Company’s officers to standardize the severance benefits offered by the Company by officer-level. Under the newly approved provisions, the following severance benefits apply to the Company’s executive officers:

<b>Position</b>	<b>Involuntary Termination/Good Reason Termination</b>	<b>Involuntary Termination/Good Reason Termination in connection with a Change in Control</b>
<b>Chief Executive Officer</b>	- 12 months base salary	- 18 months base salary
	- 12 months benefits continuation	- 18 months benefits continuation
	- Prorated current year bonus	- 1.5x current year bonus target
		- Accelerated equity vesting (double trigger)
<b>Senior Vice President</b>	- 12 months base salary	- 12 months base salary
	- 12 months benefits continuation	- 12 months benefits continuation
		- Current year bonus paid at target
		- Accelerated equity vesting (double trigger)

The Company did not make any material modifications to the applicable definitions used in connection with the severance provisions. The Compensation Committee grandfathered Mr. Furlong’s right to receive benefits continuation for 18 months if his employment is terminated involuntarily or for Good Reason in connection with a Change in Control. The Company intends to enter into new agreements with its executive officers to reflect these modifications.

**Item 6. Exhibits.**

The following is a list of exhibits filed as part of this Quarterly Report on Form 10-Q. Where so indicated, exhibits that were previously filed are incorporated by reference. For exhibits incorporated by reference, the location of the exhibit in the previous filing is indicated.

<b>Exhibit Number</b>	<b>Description</b>
10.1*	<a href="#">Consulting Agreement, dated April 1, 2021 by and between Neuronetics, Inc. and Gregory Harper.</a>
31.1*	<a href="#">Certification of the Principal Executive Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.</a>
31.2*	<a href="#">Certification of the Principal Financial Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.</a>
32.1**	<a href="#">Certification of Chief Executive Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.</a>
32.2**	<a href="#">Certification of Chief Financial Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.</a>
101.INS	Inline XBRL Instance Document – the instance document does not appear in the Interactive Data File because iXBRL tags are embedded within the Inline XBRL document.
101.SCH	Inline XBRL Taxonomy Extension Schema Document
101.CAL	Inline XBRL Taxonomy Extension Calculation Linkbase Document
101.DEF	Inline XBRL Taxonomy Extension Definition Linkbase Document
101.LAB	Inline XBRL Taxonomy Extension Label Linkbase Document
101.PRE	Inline XBRL Taxonomy Extension Presentation Linkbase Document
104	Cover Page Interactive Data File (Formatted as Inline XBRL and contained Exhibit 101).

\* Filed herewith.

\*\* This certification is being furnished solely to accompany this Quarterly Report on Form 10-Q pursuant to 18 U.S.C Section 1350 and is not being filed for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liability of that section, nor shall it be deemed incorporated by reference into any filing of the registrant under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended, whether made before or after the date hereof, regardless of any general incorporation language in such filing.

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

**NEURONETICS, INC.**

(Registrant)

Date: May 4, 2021

By: /s/ Keith J. Sullivan

Name: Keith J. Sullivan

Title: President and Chief Executive Officer  
(Principal Executive Officer)

Date: May 4, 2021

By: /s/ Stephen Furlong

Name: Stephen Furlong

Title: SVP, Chief Financial Officer and Treasurer  
(Principal Financial and Accounting Officer)



## CONSULTING AGREEMENT

This CONSULTING AGREEMENT (this “**Agreement**”), dated as April 1, 2021 (the “**Effective Date**”), is made by and between Neuronetics, Inc., a Delaware corporation (the “**Company**”), and Gregory Harper (“**Consultant**”). Consultant and the Company are sometimes individually referred to in this Agreement as a “**Party**” and collectively as the “**Parties**.”

### BACKGROUND

Consultant retired from the role of the Company’s Vice President, R&D and clinical effective March 31, 2021; and

Company desires to utilize the services of Consultant in various capacities, including facilitation of the orderly transfer of Consultant’s former responsibilities, and Consultant is willing to perform such services for Company.

### TERMS

**NOW, THEREFORE**, in consideration of the foregoing premises and the promises and covenants set forth in this Agreement and intending to be legally bound hereby, the Company and Consultant agree as follows:

#### 1. Consulting Services.

1.1. Services. During the Term (as defined in Section 3.1), Consultant shall provide the services as the Company may request from time to time (the “**Consulting Services**”) upon reasonable notice to Consultant and scheduled at mutually-convenient times. The Parties anticipate that the Consulting Services will require no more than the (10) hours per week during the Term.

1.2. Independent Contractor. Consultant and the Company intend for Consultant to be considered an independent contractor to the Company for all purposes and not an employee of the Company. The Company shall have no obligation to provide any employment-related benefits to Consultant. Consultant shall indemnify, defend and hold harmless the Company against any claim that Consultant is or was an employee of the Company after the Effective Date.

1.3. No Conflict. Consultant shall not become a party to any non-competition covenant, non-disclosure agreement or other agreement, covenant, understanding or restriction that would prohibit Consultant from executing this Agreement and performing fully his duties and responsibilities under this Agreement.

1.4. Prior Restrictive Covenants. The Parties acknowledge and agree that the Consulting Services shall have no impact on restrictive covenants granted by Consultant to the Company during the term of Consultant’s employment by the Company (“**Restrictive Covenants**”)



and the agreements containing such Restrictive Covenants shall remain in full force and effect in accordance with their respective terms.

1.5. Prior Equity Agreements. The Parties acknowledge and agree that March 31, 2021 is the date of Consultant's separation of service under any and all agreements providing for the grant of equity compensation by the Company to Consultant during the term of Consultant's employment and the agreements providing for such equity compensation shall remain in full force and effect in accordance with their respective terms.

2. Compensation.

2.1. In consideration for Consultant's performance of the Consulting Services, the Company shall pay Consultant at the rate of \$200 per hour, billed in 15 minute increments. In addition, the Company shall reimburse Consultant for reasonable and properly documented out-of-pocket expenses incurred by Consultant not to exceed \$250 without the prior written consent of the Company.

2.2. Consultant shall be solely responsible for the payment of all taxes or contributions imposed or required by the tax laws of any jurisdiction that pertain to the amounts paid to Consultant under this Agreement. The Company may issue a Form 1099 to Consultant in respect of the payments made under this Agreement.

3. Term and Termination.

3.1. Term. Subject to Section 3.2, the term of this Agreement shall begin on the Effective Date and shall continue until June 30, 2021; provided, however, that, with the mutual written consent of the Parties prior to the then-scheduled expiration date, this Agreement may be extended for successive thirty (30) day periods thereafter (the "**Term**").

3.2. Termination.

3.2.1. A Party may terminate this Agreement for convenience upon thirty (30) days' prior written notice to the other Party.

3.2.2. A Party may terminate this Agreement for breach if the other Party materially breaches any provision of this Agreement and fails to cure such breach within five (5) days after the non-breaching Party gives the other Party written notice that describes the breach in reasonable detail.

3.3. Effect of Termination. Promptly but no later than five (5) days after any termination or expiration of this Agreement, Consultant shall disclose to the Company all Inventions (as defined in Section 7.1) and deliver to the Company all work product resulting from the performance of the Consulting Services. Sections 1.2, 1.4, 1.5, 2, 3.3, 4 through 13 shall survive the termination or expiration of this Agreement for any reason in accordance with their respective



terms. Termination or expiration of this Agreement shall not be deemed to be a waiver of any claims arising from activities occurring prior to termination or expiration.

4. Non-Exclusive Engagement. The Company may from time to time (i) engage other persons and entities to act as consultants to the Company and perform services for the Company, including services that are similar to the Consulting Services, and (ii) enter into agreements similar to this Agreement with other persons or entities, in all cases without the necessity of obtaining approval from Consultant.

5. Warranty. Consultant warrants that the Consulting Services will be performed in a professional and workmanlike manner.

6. Confidentiality.

6.1. Confidential Information. Consultant agrees at all times during the Term and thereafter not to disclose to any person or entity or remove from the possession or control of the Company any Confidential Information, and not to use, except as necessary in connection with Consultant's performance of the Consulting Services or with prior written authorization of an authorized officer of the Company, any Confidential Information. As used in this Agreement, "**Confidential Information**" means any and all information concerning the Company including, without limitation, technical information concerning the Company's product development plans, the work product and other deliverables created by Consultant in connection with this Agreement, technical data, trade secrets or know-how, research, products, services, customer lists, software, developments, inventions, processes, formulas, technology, designs, drawings, engineering, marketing, distribution and sales methods and systems, sales and profit and other financial information and all other business information disclosed to Consultant by or on behalf of the Company, in each case whether disclosed in writing, orally, visually or otherwise. The foregoing restrictions shall not apply to Confidential Information, which is or becomes publicly known through no wrongful act of Consultant or the personnel of Consultant.

6.2. Consultant-Restricted Information. Consultant agrees that Consultant will not improperly use or disclose any proprietary or confidential information or trade secrets of any person or entity with whom Consultant has an agreement or duty to keep such information or secrets confidential, and will not bring onto the premises of the Company any unpublished document or proprietary information belonging to any person or entity (other than the Company or Consultant) unless consented to in writing by such person or entity.

6.3. Third Party Information. Consultant recognizes that the Company has received and in the future will receive from third parties their confidential or proprietary information subject to a duty on the Company's part to maintain the confidentiality of such information and to use it only for certain limited purposes. Consultant agrees at all times during the Term and thereafter to hold in strictest confidence, and, except as necessary in performing the Consulting Services and consistent with the Company's agreement with such third party, not to use or disclose to any person or entity such information.



6.4. Additional Obligations. Consultant acknowledges and agrees that Consultant's obligations under Section 6 are in addition to, and not in lieu of, Consultant's obligations of confidentiality as a former employee of the Company.

7. Ownership of Results.

7.1. Assignment of Inventions. Consultant agrees that Consultant will promptly make full written disclosure to the Company, will hold in trust for the sole right and benefit of the Company, and hereby assigns, transfers and conveys to the Company, or its designee, all worldwide right, title, and interest in and to any and all inventions, ideas, discoveries, original works of authorship (such as business plans, market research, reports, computer code and programs), all work product and other deliverables, findings, conclusions, data, developments, concepts, improvements, trade secrets, techniques, processes and know-how, whether or not patentable or registrable under copyright or similar laws, which Consultant may solely or jointly conceive or develop or reduce to practice, or cause to be conceived or developed or reduced to practice, in the performance of the Consulting Services or which result, to any extent, from use of the Company's premises, property or Confidential Information (collectively, the "**Inventions**"), including any and all intellectual property rights inherent in the Inventions and appurtenant thereto including, without limitation, all patent rights, copyrights, trademarks, know-how and trade secrets (collectively, "**Intellectual Property Rights**"). Consultant further acknowledges and agrees that all original works of authorship which are made by Consultant (solely or jointly with others) in the performance of the Consulting Services and which are protectable by copyright are "works made for hire," as that term is defined in the United States Copyright Act. However, to the extent that any such work may not be considered a work made for hire or Consultant otherwise retains any rights therein, Consultant hereby forever and irrevocably assigns, transfers and conveys to the Company all worldwide right, title and interest in and to such work, including all Intellectual Property Rights therein and appurtenant thereto.

7.2. Further Assurances. Upon the request and at the expense of the Company, Consultant shall execute and deliver any and all instruments and documents and take such other acts as may be necessary or desirable to document the assignment and transfer described in Section 7.1 or to enable the Company to secure its rights in the Inventions and any patents, trademarks, copyrights or other intellectual property rights relating thereto in any and all jurisdictions, or to apply for, prosecute and enforce patents, trademark registrations, copyrights or other intellectual property rights in any and all jurisdictions with respect to any Inventions, or to obtain any extension, validation, re-issue, continuance or renewal of any such intellectual property right. Without limiting the foregoing, Consultant shall disclose to the Company all pertinent information and data with respect thereto and shall execute all applications, specifications, oaths and all other instruments which the Company shall deem necessary in order to apply for and obtain such rights and in order to assign and convey to the Company the sole and exclusive right, title and interest in and to Inventions, and any patents, copyrights, trademarks or other intellectual property rights relating thereto. Consultant further agrees that Consultant's obligation to execute or cause to be executed, when it is in Consultant's power to do so, any such instrument or papers shall continue after Term. If the Company is unable for any reason to secure Consultant's signature to apply for



or to pursue any application for any United States or foreign patent, trademark, copyright or other registration covering Inventions assigned to the Company as above, then Consultant hereby irrevocably designates and appoints the Company and its duly authorized officers and agents as Consultant's agent and attorney-in-fact, to act for and in Consultant's behalf and stead to execute and file any such applications and to do all other lawfully permitted acts to further the prosecution and issuance of letters patent or trademark, copyright or other registrations thereon with the same legal force and effect as if executed by Consultant.

7.3. Pre-Existing Materials. Consultant agrees that if in the course of performing the Consulting Services, Consultant incorporates into any Invention developed hereunder any invention, improvement, development, software code, concept, discovery or other proprietary information owned by Consultant or in which Consultant has an interest: (a) Consultant shall obtain the Company's approval in writing before incorporating such invention, improvement, development, software code, concept, discovery or other proprietary information into any Invention; and (b) the Company is hereby granted and shall have a nonexclusive, royalty-free, perpetual, irrevocable, worldwide license to make, have made, copy, create derivative works of, modify, use, sell and otherwise commercialize in any manner such item as part of or in connection with such Invention (and derivatives, modifications and enhancements thereof). Consultant shall not incorporate any invention, improvement, development, software code, concept, discovery or other proprietary information owned by any third party into any Invention without the Company's prior written permission.

7.4. Warranty. Consultant hereby warrants that: (a) all Inventions will be the original work of Consultant and/or the subcontractors to Consultant; (b) the Inventions will not infringe the copyright, patent, trade secret, or any other intellectual property right of any third party; (c) the Inventions will not be obscene, libelous, or violate the right of privacy or publicity of any third party; and (d) Consultant will not intentionally insert in any Inventions any virus, trap door, worm, or any other device that is injurious or damaging to software or hardware.

7.5. Use of Subcontractors. Consultant may not use subcontractors to perform the Consulting Services except with the Company's consent in its sole and absolute discretion.

7.6. Additional Obligations. Consultant acknowledges and agrees that Consultant's obligations under Section 7 are in addition to, and not in lieu of, Consultant's obligations with respect to Inventions as a former employee of the Company.

8. Return of the Company Property. Promptly upon the expiration or termination of this Agreement or upon the Company's request at any time, Consultant shall deliver to the Company (and will not keep in Consultant's possession or deliver to anyone else) all Confidential Information and all devices, records, data, notes, reports, proposals, lists, correspondence, specifications, drawings, blueprints, sketches, materials, equipment, other documents or property, or reproductions of any aforementioned items developed by Consultant in connection with the Consulting Services or otherwise belonging to the Company. Consultant shall not remove any Company property from the premises of the Company without written authorization from the Company. Consultant acknowledges and agrees that Consultant's obligations under this Section 8



are in addition to, and not in lieu of, Consultant's obligations to return Company property as a former employee of the Company.

9. Arbitration and Equitable Relief.

9.1. Arbitration. Except as provided in Section 9.2, Consultant agrees that any dispute or controversy arising out of or relating to any interpretation, construction, performance or breach of this Agreement, shall be settled by arbitration to be held in West Chester, Pennsylvania, unless the Parties agree in writing to conduct the arbitration in another location, before a single arbitrator and in accordance with the Commercial Arbitration Rules then in effect of the American Arbitration Association. Each Party irrevocably and unconditionally consents to the jurisdiction of any such proceeding and waives any objection that it may have to personal jurisdiction or the laying of venue of any such proceeding. The Parties will cooperate with each other in causing the arbitration to be held in as efficient and expeditious a manner as practicable. If the Parties are unable to appoint a mutually acceptable arbitrator within 30 days after a Party gives written notice to the other requesting resolution of a dispute in accordance with the provisions of this Section 9.1, then the American Arbitration Association shall appoint the arbitrator in accordance with such Commercial Arbitration Rules. The arbitrator may grant injunctions or other relief in such dispute or controversy. The decision of the arbitrator shall be final, conclusive and binding on the Parties to the arbitration. Judgment may be entered on the arbitrator's decision in any court having jurisdiction. The Company and Consultant shall each pay one-half of the costs and expenses of such arbitration, and each Party shall separately pay the fees and expenses of its own counsel. Nothing in this Agreement shall prevent the Parties from settling any dispute by mutual agreement at any time.

9.2. Equitable Remedies.

9.2.1. Consultant acknowledges that Sections 6, 7, and 8 are reasonable and necessary to protect the legitimate interests of the Company and its affiliates, that the Company would not have entered into this Agreement in the absence of such provisions, that it would be impossible or inadequate to measure and calculate the Company's damages from any violation of those Sections and that any violation of any provision of those Sections may result in irreparable injury to the Company and its affiliates (each of which shall be deemed a third party beneficiary of such restriction). Consultant agrees that each of the Company and its affiliates shall be entitled to obtain from any court of competent jurisdiction (and, for the avoidance of doubt, without resort to arbitration as provided in Section 9.1) preliminary and permanent injunctive relief and to specific performance of any such provision of this Agreement, without the necessity of proving actual damages, as well as to an equitable accounting of all earnings, profits and other benefits arising from any violation of Sections 6, 7, and 8 which rights shall be cumulative and in addition to any other rights or remedies to which the Company or any affiliate may be entitled. Consultant further agrees that no bond or other security shall be required in obtaining such equitable relief and Consultant hereby consents to the issuance of such injunction and to the ordering of specific performance.



9.2.2. Consultant irrevocably and unconditionally: (i) agrees that any suit, action or other legal proceeding seeking equitable relief under this Section 9, including without limitation, any action commenced by the Company for preliminary and permanent injunctive relief and other equitable relief, may be brought in any court of competent jurisdiction; (ii) consents to the non-exclusive jurisdiction of any such court in any such suit, action or proceeding; and (iii) waives any objection which Consultant may have to the laying of venue of any such suit, action or proceeding in any such court. Consultant also irrevocably and unconditionally consents to the service of any process, pleading, notices or other papers in any manner permitted by the notice provisions of Section 9.

10. Governing Law. This Agreement shall be governed by the laws of the Commonwealth of Pennsylvania, without regard to the conflict of law principles of any jurisdiction.

11. Notices. All notices and other communications under this Agreement or in connection with this Agreement shall be in writing and shall be deemed to have been given and received upon the earlier of (a) actual receipt by the intended recipient or (b) one (1) business day after deposit of the notice with a nationally-recognized overnight delivery service, properly addressed and charges prepaid as follows:

If to the Company, to:

Neuronetics, Inc.  
3222 Phoenixville Pike  
Malvern, PA 19355  
Attention: General Counsel

If to Consultant, to:

Gregory Harper  
[INSERT ADDRESS]

or to such other names, addresses and/or facsimile numbers as the Company or Consultant, as the case may be, shall designate by notice to the other person in the manner specified in this Section.

12. Severability. The provisions of this Agreement are severable, and if any provision or portion thereof is held to be invalid or unenforceable for any reason, such provision or portion thereof shall be modified or adjusted by a court or other tribunal exercising its equitable powers to the extent necessary to cure such invalidity or unenforceability, and all other covenants and provisions shall remain valid and enforceable.

13. Miscellaneous. This Agreement: (a) constitutes the final, exclusive and fully integrated agreement between the Company and Consultant with respect to its subject matter and supersedes any prior and contemporaneous agreements and understandings between the Company and Consultant relating to the subject matter of this Agreement; (b) may be modified only in a writing duly executed by the Party against whom enforcement is sought; and (c) shall be binding upon and



inure to the benefit of and be enforceable by the respective successors and assigns of the Parties to this Agreement; provided that this Agreement may be assigned by the Company at any time; and provided further that Consultant acknowledges that the duties and responsibilities of Consultant are of a personal nature and, as such, this Agreement and the rights and responsibilities of Consultant may not be assigned or delegated in whole or in part, by Consultant without the prior written consent of the Company, except that Consultant may assign its right to payments due under this Agreement by giving the Company written notice of assignment that includes the name and address of the assignee and an acknowledgement acceptable to the Company that payment to the assignee satisfies the Company's payment obligations under this Agreement to the extent of the payment. This Agreement may be signed in counterparts which, when taken together, shall be one and the same document. The headings of the Sections of this Agreement are for convenience of reference only.

IN WITNESS WHEREOF, the undersigned have executed this Agreement as of the Effective Date.

NEURONETICS, INC.

By: /s/ Keith J. Sullivan

Name: Keith J. Sullivan

Title: President and Chief Executive Officer

By: /s/ Gregory Harper

Name: Gregory Harper

---

CERTIFICATION OF CHIEF EXECUTIVE OFFICER

I, Keith J. Sullivan, certify that:

1. I have reviewed this quarterly report on Form 10-Q of Neuronetics, Inc.;
2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4. The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) for the registrant and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
  - (a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
  - (b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
  - (c) Evaluated the effectiveness of the registrant's disclosure controls and procedures, and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures as of the end of the period covered by this report based on such evaluation; and
  - (d) Disclosed in this report, any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and
5. The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):
  - (a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and
  - (b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

Date: May 4, 2021

By: /s/ Keith J. Sullivan

Name: Keith J. Sullivan

Title: President and Chief Executive Officer  
(Principal Executive Officer)

---

CERTIFICATION OF CHIEF FINANCIAL OFFICER

I, Stephen Furlong, certify that:

1. I have reviewed this quarterly report on Form 10-Q of Neuronetics, Inc.;
2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4. The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
  - (a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
  - (b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
  - (c) Evaluated the effectiveness of the registrant's disclosure controls and procedures, and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures as of the end of the period covered by this report based on such evaluation; and
  - (d) Disclosed in this report, any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and
5. The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):
  - (a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and
  - (b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

Date: May 4, 2021

By: /s/ Stephen Furlong

Name: Stephen Furlong

Title: SVP, Chief Financial Officer and Treasurer  
(Principal Financial and Accounting Officer)

---

**CERTIFICATION PURSUANT TO  
18 U.S.C. SECTION 1350,  
AS ADOPTED PURSUANT TO  
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002**

In connection with the quarterly report on Form 10-Q of Neuronetics, Inc. (the "Company") for the fiscal quarter ended March 31, 2021 as filed with the Securities and Exchange Commission on the date hereof (the "Report"), I certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:

- (1) the Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and
- (2) the information contained in the Report fairly presents, in all material respects, the financial condition and result of operations of the Company.

Date: May 4, 2021

By: /s/ Keith J. Sullivan

Name: Keith J. Sullivan

Title: President and Chief Executive Officer  
(Principal Executive Officer)

---

**CERTIFICATION PURSUANT TO  
18 U.S.C. SECTION 1350,  
AS ADOPTED PURSUANT TO  
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002**

In connection with the quarterly report on Form 10-Q of Neuronetics, Inc. (the "Company") for the fiscal quarter ended March 31, 2021 as filed with the Securities and Exchange Commission on the date hereof (the "Report"), I certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:

- (1) the Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and
- (2) the information contained in the Report fairly presents, in all material respects, the financial condition and result of operations of the Company.

Date: May 4, 2021

By: /s/ Stephen Furlong

Name: Stephen Furlong

Title: SVP, Chief Financial Officer and Treasurer  
(Principal Financial and Accounting Officer)

---